PubmedID,Title,Publication Date,Non-academic Author(s),Company Affiliation(s),Corresponding Author Email
38469154,Circulating IL-6 and not its circulating signaling components sIL-6R and sgp130 demonstrate clinical significance in NSCLC patients treated with immune checkpoint inhibitors.,2023,"Miura, Masatomo; Fujita, Kazuma","Department of Pharmacy, Akita University Hospital, Akita, Japan.; Department of Pharmacy, Akita University Hospital, Akita, Japan.",None
38378398,Transitioning to Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: Trends and Surgical Outcomes in a Regionalized Pulmonary Oncology Network.,2024,"Wong, Annick","Department of Oncology, McGill University, Montreal, QC, Canada; Hôpital du Suroît, Salaberry-de-Valleyfield, QC, Canada.",jonathan.spicer@mcgill.ca.
38322280,Treatment decision for recurrences in non-small cell lung cancer during or after adjuvant osimertinib: an international Delphi consensus report.,2023,"Leighl, Natasha; Wu, Yi-Long","Department of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.",None
38304857,"RELAY, Erlotinib Plus Ramucirumab in Untreated, ",2024,"Carlsen, Michelle","Eli Lilly and Company, Indianapolis, Indiana.",None
38262770,"APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research.",2024,"Inno, Alessandro","Oncology Department, IRCCS Ospedale Sacro Cuore don Calabria, Verona, Italy.",Leonardo.provenzano@istitutotumori.mi.it.
38245456,Brief Report: Updated Efficacy and Safety Data From an Integrated Analysis of Entrectinib in Locally Advanced/Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.,2024,"Krzakowski, Maciej; Zeuner, Harald; Xue, Cloris","Lung Cancer and Thoracic Cancer Department, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; F. Hoffmann-La Roche Ltd, Mississauga, Canada.",matthew.krebs@manchester.ac.uk.
38218680,Prognostic Impact of TP53 Mutations in Metastatic Nonsquamous Non-small-cell Lung Cancer.,2024,"Denis, Marc G; Herbreteau, Guillaume","Nantes Université, CHU Nantes, Department of Biochemistry, INSERM, CNRS, Immunology and New Concepts in ImmunoTherapy, INCIT, Nantes, France.; Nantes Université, CHU Nantes, Department of Biochemistry, INSERM, CNRS, Immunology and New Concepts in ImmunoTherapy, INCIT, Nantes, France.",judith.raimbourg@ico.unicancer.fr.
38190787,"EGFR-mutation testing, treatment patterns and clinical outcomes in patients with stage IB-IIIA non-small cell lung cancer in Norway-a nationwide cohort study.",2024,"Conte, Simona; Frederiksen, Line Elmerdahl; Aarøe, Jørgen","Medical, Biopharmaceuticals, AstraZeneca, Stockholm, Sweden.; Medical, Biopharmaceuticals, AstraZeneca, Copenhagen, Denmark.; Medical, Biopharmaceuticals, AstraZeneca, Oslo, Norway.",espen.enerly@kreftregisteret.no.
38185589,"PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial.",2024/Feb/26,"Huang, Jie; Deng, Jia-Yi; Xu, Chong-Rui; Yan, Hong-Hong; Yang, Ming-Yi; Li, Yang-Si; Ke, E-E; Zheng, Ming-Ying; Wang, Zhen; Lin, Jia-Xin; Gan, Bin; Zhang, Xu-Chao; Chen, Hua-Jun; Wang, Bin-Chao; Tu, Hai-Yan; Yang, Jin-Ji; Zhong, Wen-Zhao; Li, Yangqiu; Zhou, Qing; Wu, Yi-Long","Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China; Chinese Thoracic Oncology Group (CTONG), Guangzhou 510055, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China.; Department of Hematology, The First Affiliated Hospital, Jinan University, Guangzhou 510632, China; Institute of Hematology, School of Medicine, Key Laboratory for Regenerative Medicine of Ministry of Education, Jinan University, Guangzhou 510632, China. Electronic address: yangqiuli@hotmail.com.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China; Chinese Thoracic Oncology Group (CTONG), Guangzhou 510055, China. Electronic address: gzzhouqing@126.com.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China; Chinese Thoracic Oncology Group (CTONG), Guangzhou 510055, China. Electronic address: syylwu@live.cn.",syylwu@live.cn.
38159809,"Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial.",2024,"Okpara, Chinyere E; Dutcus, Corina; Zimmer, Zachary; Samkari, Ayman; Bhagwati, Niyati","Eisai Ltd., Hatfield, United Kingdom.; Eisai Inc., Nutley, New Jersey.; Merck & Co., Inc., Rahway, New Jersey.; Merck & Co., Inc., Rahway, New Jersey.; Merck & Co., Inc., Rahway, New Jersey.",chihyang@ntu.edu.tw.
38154514,Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC.,2024,"Bachert, Sara Emily; Zhang, Tom; Lockwood, William W; Ladanyi, Marc; Somwar, Romel","Department of Pathology and Laboratory Medicine, University of Kentucky, Lexington, Kentucky.; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; School of Medicine, New York Medical College, Valhalla, New York.; Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.",lmsholl@bwh.harvard.edu.
38141488,Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: Results of an international expert panel meeting by the italian association of thoracic oncology (AIOT).,2024,"Mok, Tony","Department of Clinical Oncology, Faculty of Medicine, State Key Laboratory in Oncology in South China, The Chinese University of Hong Kong, Hong Kong Special Administrative Region.",cgridelli@libero.it.
38110665,A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer.,2024,"Duan, Huaxin; Li, Baiyong; Xia, Yu","Department of Oncology, Hunan Provincial People's Hospital /The First Affiliated Hospital of Hunan Normal University, Changsha, China.; Akeso Biopharma, Inc, Zhongshan, China.; Akeso Biopharma, Inc, Zhongshan, China.",wulin-calf@vip.163.com.
38105153,Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer.,2024,"Albarrán-Artahona, Víctor; Reyes, Roxana; Mezquita, Laura","Medical Oncology Department, Department of Medicine, Hospital Clinic, Laboratory of Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, University of Barcelona, Barcelona, Spain.; Medical Oncology Department, Department of Medicine, Hospital Clinic, Laboratory of Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, University of Barcelona, Barcelona, Spain.; Medical Oncology Department, Department of Medicine, Hospital Clinic, Laboratory of Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, University of Barcelona, Barcelona, Spain. Electronic address: lmezquita@clinic.cat.",lmezquita@clinic.cat.
38104577,"Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study.",2024/Jan/13,"Tsai, Chiaojung Jillian; Patel, Juber; Berger, Michael; Reis-Filho, Jorge S","Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. Electronic address: jillian.tsai@uhn.ca.; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.",jillian.tsai@uhn.ca.
38100106,Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer.,2023/Dec/01,"Nishimura, Kunihiro; Hiraoka, Manabu","Xcoo Inc, Tokyo, Japan.; Japan Medical Affairs, Japan Oncology Business Unit, Takeda Pharmaceutical Company Limited, Tokyo, Japan.",None
38096471,Treating Early and Often: Targeted Therapeutics in the Adjuvant Setting.,2023,"Ganesan, Shridar","Rutgers Cancer Institute of New Jersey, Department of Medicine and Pharmacology, Rutgers Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ.",None
38070301,Understanding health-related quality of life measures used in early-stage non-small cell lung cancer clinical trials: A review.,2024,"Leighl, Natasha B","Division of Medical Oncology/Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.",MMajem@santpau.cat.
38057314,Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study.,2023/Dec/06,"Liu, Si-Yang; Dong, Song; Yang, Xue-Ning; Liao, Ri-Qiang; Jiang, Ben-Yuan; Ben, Xiao-Song; Qiao, Gui-Bin; Lin, Jun-Tao; Yan, Hong-Hong; Yan, Li-Xu; Nie, Qiang; Tu, Hai-Yan; Wang, Bin-Chao; Yang, Jin-Ji; Zhou, Qing; Li, Hong-Rui; Liu, Ke; Wu, Wendy; Zhong, Wen-Zhao; Wu, Yi-Long","Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.; Department of Thoracic Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.; Department of Thoracic Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.; Department of Pathology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.; Fujian Key Laboratory of Advanced Technology for Cancer Screening and Early Diagnosis, Fuzhou, China.; Fujian Key Laboratory of Advanced Technology for Cancer Screening and Early Diagnosis, Fuzhou, China.; Fujian Key Laboratory of Advanced Technology for Cancer Screening and Early Diagnosis, Fuzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China. syzhongwenzhao@scut.edu.cn.; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China. syylwu@live.cn.",syylwu@live.cn.
38049664,The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance.,2024,"Caswell, Deborah R; Pich, Oriol; Bailey, Chris; Boumelha, Jesse; Bakker, Bjorn; De Dios Palomino Villcas, Juan; Dietzen, Michelle; Angelova, Mihaela; Humpton, Timothy J; Hill, William; Tomaschko, Mona; Lu, Wei-Ting; Al Bakir, Maise; Nagano, Ai; de Carné Trécesson, Sophie; Vendramin, Roberto; Barbè, Vittorio; Weeden, Clare E; Rowan, Andrew; McCoach, Caroline E; Moore, Chris; Przewrocka, Joanna; Black, James R M; Grönroos, Eva; Venkatesan, Subramanian; Roper, Nitin; Chew, Su Kit; Vousden, Karen H; Downward, Julian; Bivona, Trever G; Swanton, Charles","Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK. deborah.caswell@crick.ac.uk.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Oncogene Biology Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Core Research Laboratory, ISPRO, Florence, Italy.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; p53 and Metabolism Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Oncogene Biology Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Oncogene Biology Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Genentech Inc, South San Francisco, CA, USA.; Oncogene Biology Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; p53 and Metabolism Laboratory, The Francis Crick Institute, London, UK.; Oncogene Biology Laboratory, The Francis Crick Institute, London, UK.; Departments of Medicine and Cellular and Molecular Pharmacology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA. trever.bivona@ucsf.edu.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.",trever.bivona@ucsf.edu.
38035705,Circular RNA in Non-small Cell Lung Carcinoma: Identification of Targets and New Treatment Modalities.,2023,"Weidle, Ulrich H; Birzele, Fabian","Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany; weidle49@t-online.de.; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland fabian.birzele@roche.com.",fabian.birzele@roche.com.
38030303,"Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors.",2023/Nov/29,"Bauer, Todd M; Greil, Richard; Spreafico, Anna; Lu, Darlene; Cremasco, Viviana; Pelletier, Marc; Doi, Toshikiko","Sarah Cannon Research Institute, Nashville, Tennessee, USA.; Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Paracelsus Medical University Salzburg, Salzburg, Austria.; Department of Medicine, Division of Medical Oncology and Hematology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada.; Novartis Institutes for BioMedical Research Inc, Cambridge, Massachusetts, USA.; Novartis Institutes for BioMedical Research Inc, Cambridge, Massachusetts, USA.; Novartis Institutes for BioMedical Research Inc, Cambridge, Massachusetts, USA.; Department of Experimental Therapeutics, National Cancer Center-Hospital East, Kashiwa, Chiba, Japan tdoi@east.ncc.go.jp.",tdoi@east.ncc.go.jp.
38025806,Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study.,2023/Oct/31,"Camps, Carlos; Penrod, John; Vo, Lien","Molecular Oncology Laboratory, Valencia University General Hospital, Valencia, Spain.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.",None
38012986,Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC.,2024,"Wang, Kaiwen; Lewis, Whitney E","Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas.",xle1@mdanderson.org.
38001689,C-Reactive Protein as an Early Predictor of Efficacy in Advanced Non-Small-Cell Lung Cancer Patients: A Tumor Dynamics-Biomarker Modeling Framework.,2023/Nov/15,"Nassar, Yomna M; Ojara, Francis Williams; Pérez-Pitarch, Alejandro; Geiger, Kimberly; Michelet, Robin; Holdenrieder, Stefan; Kloft, Charlotte","Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universität Berlin, 12169 Berlin, Germany.; Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universität Berlin, 12169 Berlin, Germany.; Translational Medicine & Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, 55216 Ingelheim am Rhein, Germany.; Institute of Laboratory Medicine, German Heart Centre Munich of the Free State of Bavaria, Technical University Munich, 80636 Munich, Germany.; Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universität Berlin, 12169 Berlin, Germany.; Institute of Laboratory Medicine, German Heart Centre Munich of the Free State of Bavaria, Technical University Munich, 80636 Munich, Germany.; Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universität Berlin, 12169 Berlin, Germany.",None
38001589,Amivantamab Compared with Real-World Physician's Choice after Platinum-Based Therapy from a Pan-European Chart Review of Patients with Lung Cancer and Activating ,2023/Nov/08,"Diels, Joris; Schioppa, Claudio A; Sermon, Jan; Rahhali, Nora; Adamczyk, Agnieszka; Penton, James","Janssen Pharmaceutica NV, 2340 Beerse, Belgium.; Janssen Pharmaceutica NV, 2340 Beerse, Belgium.; Janssen Pharmaceutica NV, 2340 Beerse, Belgium.; Janssen-Cilag Ltd., 92130 Issy-les-Moulineaux, France.; Janssen-Cilag Ltd., 28042 Madrid, Spain.; Janssen-Cilag Ltd., High Wycombe HP12 4EG, UK.",None
37992688,Aurora A kinase inhibition induces accumulation of SCLC tumor cells in mitosis with restored interferon signaling to increase response to PD-L1.,2023/Nov/21,"Poitras, Michael J; Springer, Benjamin F; Southard, Jackson; Li, Shuqiang; Gokhale, Prafulla C","Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Experimental Therapeutics Core, Dana-Farber Cancer Institute, Boston, MA 02210, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Experimental Therapeutics Core, Dana-Farber Cancer Institute, Boston, MA 02210, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA; Translational Immunogenomics Lab, Dana Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA; Translational Immunogenomics Lab, Dana Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Experimental Therapeutics Core, Dana-Farber Cancer Institute, Boston, MA 02210, USA.",matthew_oser@dfci.harvard.edu.
37992595,"Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON).",2023,"Alatorre-Alexander, Jorge; Geater, Sarayut Lucien; Hussein, Maen; Araujo, Luiz Henrique; Johnson, Melissa","Health Pharma Professional Research, Mexico City, Mexico.; Prince of Songkla University, Songkhla, Thailand.; Florida Cancer Specialists - Sarah Cannon Research Institute, Leesburg, FL, USA.; Instituto Nacional de Cancer-INCA, Rio de Janeiro, Brazil.; Sarah Cannon Research Institute, Tennessee Oncology, PLLC, Nashville, TN, USA.",egaron@mednet.ucla.edu.
37981090,"Pan-Tumor Analytical Validation and Osimertinib Clinical Validation in EGFR Mutant Non-Small-Cell Lung Cancer, Supporting the First Next-Generation Sequencing Liquid Biopsy in Vitro Diagnostic.",2024,"Wu, Yi-Long","Guangdong Lung Cancer Institute, Guangdong Provincial Peoples Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.",jodegaard@guardanthealth.com.
37979367,"Validated extended multiplexed LC-MS/MS assay for the quantification of adagrasib and sotorasib in human plasma, together with four additional SMIs.",2023/Dec/01,"Kruithof, Paul D; de Beer, Yvo M; Gulikers, Judith L; Stolk, Leo M L; Croes, Sander; van Geel, Robin M J M","Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Center+, AZ, Maastricht, the Netherlands; CARIM School for Cardiovascular Disease, Maastricht University Medical Center+, MD, Maastricht, the Netherlands.; Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Center+, AZ, Maastricht, the Netherlands.; Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Center+, AZ, Maastricht, the Netherlands; CARIM School for Cardiovascular Disease, Maastricht University Medical Center+, MD, Maastricht, the Netherlands.; Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Center+, AZ, Maastricht, the Netherlands.; Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Center+, AZ, Maastricht, the Netherlands; CARIM School for Cardiovascular Disease, Maastricht University Medical Center+, MD, Maastricht, the Netherlands.; Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Center+, AZ, Maastricht, the Netherlands; CARIM School for Cardiovascular Disease, Maastricht University Medical Center+, MD, Maastricht, the Netherlands. Electronic address: robin.van.geel@mumc.nl.",robin.van.geel@mumc.nl.
37968730,Baseline extracellular vesicle miRNA-30c and autophagic CTCs predict chemoradiotherapy resistance and outcomes in patients with lung cancer.,2023/Nov/15,"Expósito Hernández, Jose","Biomedical Research Institute IBS-Granada, Avda. de Madrid, 15, Granada, 18012, Spain.",mjose.serrano@genyo.es.
37966566,Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study).,2023,"Dhamelincourt, Estelle","Institut de Cancérologie, Hôpital Morvan, CHU de Brest, Brest, France. Estelle.dhamelincourt@chu-brest.fr.",Estelle.dhamelincourt@chu-brest.fr.
37951954,Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial.,2023/Nov/11,"Schenker, Michael","Sf Nectarie Oncology Center, 23 Strada Caracal, Craiova, Județul Dolj, Romania, and the University of Medicine and Pharmacy, Craiova, Romania.",LIMLOVE2008@yuhs.ac.
37951206,"IPSOS trial: A ""game changer"" redefining first-line immunotherapy in platinum-ineligible NSCLC.",2023/Nov/10,"Mezquita, Laura","Department of Medical Oncology, Hospital Clinic de Barcelona, Barcelona, Spain; Laboratory of Translational Genomic and Targeted therapies in Solid Tumors, IDIBAPS, Barcelona, Spain; Department of Medicine, University of Barcelona, Barcelona, Spain. Electronic address: lmezquita@clinic.cat.",lmezquita@clinic.cat.
37933916,"Association between treatment and improvements in overall survival of patients with advanced/metastatic non-small cell lung cancer since 2011: A study in the United States, Canada, and Germany using retrospective real-world databases.",2024/Feb/15,"Wilke, Thomas; Froelich, Carolin","Institut für Pharmakoökonomie und Arzneimittellogistik e.V., University of Wismar, Wismar, Germany.; Roche Pharma AG, Grenzach-Wyhlen, Germany.",None
37918061,High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors.,2023,"Torri, Valter","Methodology for Clinical Research Laboratory, Istituto di Ricerche Farmacologiche Mario Negri Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy.",ferrara.roberto@hsr.it.
37916501,Pralsetinib in patients with RET fusion-positive non-small-cell lung cancer: A plain language summary of the ARROW study.,2024,"Subbiah, Vivek; Smoljanovic, Vlatka; Rahman, Ahmadur; Zalutskaya, Alena; Louie-Gao, Melinda; Boral, Andy L","Sarah Cannon Research Institute, Nashville, TN, USA.; F. Hoffmann-La Roche, Ltd, Basel, Switzerland.; F. Hoffmann-La Roche, Ltd, Basel, Switzerland.; Blueprint Medicines Corporation, Cambridge, MA, USA.; Blueprint Medicines Corporation, Cambridge, MA, USA.; Blueprint Medicines Corporation, Cambridge, MA, USA.",None
37916173,Characterization of a cohort of metastatic lung cancer patients harboring ,2023,"Notario, Lucía; Cucurull, Marc; Cerdà, Gabriela; Sanz, Carolina; Carcereny, Enric; Muñoz-Mármol, Ana; Hernández, Ainhoa; Domènech, Marta; Morán, Teresa; Sánchez-Céspedes, Montse; Costa, Marta; Mate, Jose-Luis; Esteve, Anna; Saigí, Maria","Medical Oncology Department, Catalan Institute of Oncology (ICO)-Badalona, Germans Trias i Pujol University Hospital (HUGTiP), Badalona-Applied Research Group in Oncology (B-ARGO), Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain.; Medical Oncology Department, Catalan Institute of Oncology (ICO)-Badalona, Germans Trias i Pujol University Hospital (HUGTiP), Badalona-Applied Research Group in Oncology (B-ARGO), Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain.; Medical Oncology Department, Catalan Institute of Oncology (ICO)-Badalona, Germans Trias i Pujol University Hospital (HUGTiP), Badalona-Applied Research Group in Oncology (B-ARGO), Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain.; Pathology Department, Germans Trias i Pujol University Hospital (HUGTiP), Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain.; Medical Oncology Department, Catalan Institute of Oncology (ICO)-Badalona, Germans Trias i Pujol University Hospital (HUGTiP), Badalona-Applied Research Group in Oncology (B-ARGO), Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain.; Pathology Department, Germans Trias i Pujol University Hospital (HUGTiP), Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain.; Medical Oncology Department, Catalan Institute of Oncology (ICO)-Badalona, Germans Trias i Pujol University Hospital (HUGTiP), Badalona-Applied Research Group in Oncology (B-ARGO), Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain.; Medical Oncology Department, Catalan Institute of Oncology (ICO)-Badalona, Germans Trias i Pujol University Hospital (HUGTiP), Badalona-Applied Research Group in Oncology (B-ARGO), Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain.; Medical Oncology Department, Catalan Institute of Oncology (ICO)-Badalona, Germans Trias i Pujol University Hospital (HUGTiP), Badalona-Applied Research Group in Oncology (B-ARGO), Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain.; Cancer Genetics Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Spain.; Badalona-Applied Research Group in Oncology (B-ARGO), Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain.; Pathology Department, Germans Trias i Pujol University Hospital (HUGTiP), Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain.; Statistics Department, Catalan Institute of Oncology (ICO)-Badalona, Applied Research Group in Oncology (B-ARGO), Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain.; Medical Oncology Department, Catalan Institute of Oncology (ICO)-Badalona, Germans Trias i Pujol University Hospital (HUGTiP), Badalona-Applied Research Group in Oncology (B-ARGO), Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain.",None
37897879,"Characteristics, management, and healthcare resources of patients with advanced non-small-cell lung cancer surviving 5 years after nivolumab treatment initiation: A national database analysis.",2023,"Assié, Jean-Baptiste; Grumberg, Valentine","Functional Genomics of Solid Tumors Laboratory, Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Paris, France; Centre Hospitalier Intercommunal Créteil, Créteil, France.; Bristol Myers Squibb France, 3 rue Joseph Monier, Rueil-Malmaison 92500, France; Oncostat - U1018, INSERM, Paris Saclay University, ""Ligue Contre le Cancer"" Labeled Team, Villejuif, France. Electronic address: Valentine.grumberg@bms.com.",Valentine.grumberg@bms.com.
37897014,Impact of Tyrosine Kinase Inhibitors on the Immune Response to SARS-CoV-2 Vaccination in Patients with Non-Small Cell Lung Cancer.,2023/Oct/19,"Hernández-Pedro, Norma; Barrios-Bernal, Pedro; Romero-Nuñez, Eunice","Laboratorio de Medicina Personalizada, Instituto Nacional de Cancerología, S.S.A., San Fernando 22 Sección XVI, Tlalpan, Mexico City 14080, Mexico.; Laboratorio de Medicina Personalizada, Instituto Nacional de Cancerología, S.S.A., San Fernando 22 Sección XVI, Tlalpan, Mexico City 14080, Mexico.; Laboratorio de Medicina Personalizada, Instituto Nacional de Cancerología, S.S.A., San Fernando 22 Sección XVI, Tlalpan, Mexico City 14080, Mexico.",None
37879444,Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.,2024,"Kowalski, D M","Department of Lung Cancer and Thoracic Tumours, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.",antonio.passaro@ieo.it.
37879443,Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review.,2024,"Prelaj, A; Miskovic, V; Trovo, F; Mazzeo, L; Favali, M; Ambrosini, E; Turajlic, S; Spencer, C; Pedrocchi, A L G","Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, Milan; Nearlab, Department of Electronics, Information, and Bioengineering, Politecnico di Milano, Milano, Italy; ESMO Real World Data and Digital Health Working Group, ESMO, Lugano, Switzerland. Electronic address: arsela.prelaj@istitutotumori.mi.it.; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, Milan; Nearlab, Department of Electronics, Information, and Bioengineering, Politecnico di Milano, Milano, Italy.; Nearlab, Department of Electronics, Information, and Bioengineering, Politecnico di Milano, Milano, Italy.; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, Milan; Nearlab, Department of Electronics, Information, and Bioengineering, Politecnico di Milano, Milano, Italy.; Nearlab, Department of Electronics, Information, and Bioengineering, Politecnico di Milano, Milano, Italy.; Nearlab, Department of Electronics, Information, and Bioengineering, Politecnico di Milano, Milano, Italy.; Cancer Dynamics Laboratory, The Francis Crick Institute, London.; Cancer Dynamics Laboratory, The Francis Crick Institute, London. Electronic address: Charlotte.spencer@crick.ac.uk.; Nearlab, Department of Electronics, Information, and Bioengineering, Politecnico di Milano, Milano, Italy.",Charlotte.spencer@crick.ac.uk.
37877248,Comparison of two-stage and joint TGI-OS modeling using data from six atezolizumab clinical studies in patients with metastatic non-small cell lung cancer.,2024,"Chan, Phyllis; Jin, Jin Y; Bruno, René","Clinical Pharmacology, Genentech, South San Francisco, California, USA.; Clinical Pharmacology, Genentech, South San Francisco, California, USA.; Clinical Pharmacology, Genentech-Roche, Marseille, France.",None
37871779,Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trials.,2023,"Santini, Daniele","Division of Medical Oncology A, Policlinico Umberto I, Rome, Italy; Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University, Latina, Italy.",filippogallina92@gmail.com.
37866811,SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.,2024,"Reynolds, C; Percent, I; Johnson, M L; Shazer, R L; Yan, X; Harrigan, R","Ocala Cancer Center, Florida Cancer Specialists and Research Institute - North Region (SCRI), Ocala, USA.; North Port Cancer Center, Florida Cancer Specialists and Research Institute - South Region (SCRI), Port Charlotte, USA.; Department of Medical Oncology, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, USA.; Department of Clinical Research and Development, Mirati Therapeutics, Inc., San Diego, USA.; Department of Clinical Research and Development, Mirati Therapeutics, Inc., San Diego, USA.; Department of Clinical Research and Development, Mirati Therapeutics, Inc., San Diego, USA.",Hossein.Borghaei@fccc.edu.
37860193,Significant changes in advanced lung cancer survival during the past decade in Hungary: impact of modern immunotherapy and the COVID-19 pandemic.,2023,"Kiss, Zoltán; Hódi, Gábor; Polányi, Zoltán; Kovács, Krisztina; Knollmajer, Kata; Szabó, Tamás G; Berta, Andrea; Rokszin, György; Abonyi-Tóth, Zsolt; Barcza, Zsófia","MSD Pharma Hungary Ltd, Budapest, Hungary.; MSD Pharma Hungary Ltd, Budapest, Hungary.; MSD Pharma Hungary Ltd, Budapest, Hungary.; MSD Pharma Hungary Ltd, Budapest, Hungary.; MSD Pharma Hungary Ltd, Budapest, Hungary.; MSD Pharma Hungary Ltd, Budapest, Hungary.; MSD Pharma Hungary Ltd, Budapest, Hungary.; RxTarget Ltd., Szolnok, Hungary.; RxTarget Ltd., Szolnok, Hungary.; Syntesia Ltd, Budapest, Hungary.",None
37853341,Pan-tumor survey of ROS1 fusions detected by next-generation RNA and whole transcriptome sequencing.,2023/Oct/18,"Raez, Luis E","Memorial Healthcare System/Florida Atlantic University, Pembroke Pines, FL, USA.",nagasakm@hs.uci.edu.
37852738,Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer.,2023,"Wang, Kun; Ruppin, Eytan","Cancer Data Science Lab, National Cancer Institute, National Institute of Health, Bethesda, Maryland, USA.; Cancer Data Science Lab, National Cancer Institute, National Institute of Health, Bethesda, Maryland, USA.",alessiocortellini@gmail.com
37848757,Improved survival outcome with not-delayed radiotherapy and immediate PD-1/PD-L1 inhibitor for non-small-cell lung cancer patients with brain metastases.,2023,"Yu, Yaner; Chen, Haiyan; Tian, Zhifeng; Shui, Yongjie; Shen, Li; Hu, Qiongge; Wei, Qichun","Department of Radiation Oncology (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, Key Laboratory of Molecular Biology in Medical Sciences, Zhejiang Province, China), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Department of Radiation Oncology (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, Key Laboratory of Molecular Biology in Medical Sciences, Zhejiang Province, China), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Department of Radiation Oncology (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, Key Laboratory of Molecular Biology in Medical Sciences, Zhejiang Province, China), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Department of Radiation Oncology (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, Key Laboratory of Molecular Biology in Medical Sciences, Zhejiang Province, China), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Department of Radiation Oncology (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, Key Laboratory of Molecular Biology in Medical Sciences, Zhejiang Province, China), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Department of Radiation Oncology (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, Key Laboratory of Molecular Biology in Medical Sciences, Zhejiang Province, China), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Department of Radiation Oncology (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, Key Laboratory of Molecular Biology in Medical Sciences, Zhejiang Province, China), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. qichun_wei@zju.edu.cn.",qichun_wei@zju.edu.cn.
37848034,Differential network analysis of ROS1 inhibitors reveals lorlatinib polypharmacology through co-targeting PYK2.,2024/Feb/15,"Liao, Yi; Remsing Rix, Lily L; Li, Xueli; Fang, Bin; Izumi, Victoria; Welsh, Eric A; Monastyrskyi, Andrii; Haura, Eric B; Koomen, John M; Rix, Uwe","Department of Drug Discovery, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.; Department of Drug Discovery, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.; Department of Drug Discovery, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.; Proteomics and Metabolomics Core, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.; Proteomics and Metabolomics Core, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.; Biostatistics and Bioinformatics Shared Resource, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.; Department of Drug Discovery, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA; Department of Oncologic Sciences, University of South Florida, Tampa, FL 33620, USA.; Department of Thoracic Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.; Department of Oncologic Sciences, University of South Florida, Tampa, FL 33620, USA; Department of Molecular Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.; Department of Drug Discovery, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA; Department of Oncologic Sciences, University of South Florida, Tampa, FL 33620, USA. Electronic address: uwe.rix@moffitt.org.",uwe.rix@moffitt.org.
37839252,Characterization of 164 patients with NRAS mutated non-small cell lung cancer (NSCLC).,2023,"Chour, Ali; Munck, Camille","Respiratory Department, Louis Pradel Hospital, Hospices Civils de Lyon Cancer Institute, Lyon, France; Oncopharmacology Laboratory, Cancer Research Center of Lyon, UMR INSERM 1052 CNRS 5286, Lyon, France; Université Claude Bernard, Université de Lyon, Lyon, France.; Pneumologie, Hôpital Saint Vincent de Paul, Lille, France.",simon.baldacci@univ-lille2.fr.
37827156,Inhibition of a lower potency target drives the anticancer activity of a clinical p38 inhibitor.,2023/Oct/19,"Ashtekar, Kumar Dilip; Smith, Joan C; Heppner, David E","Yale University School of Medicine, New Haven, CT 06511, USA; Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06511, USA; Yale Cancer Biology Institute, West Haven, CT 06516, USA.; Yale University School of Medicine, New Haven, CT 06511, USA; Meliora Therapeutics, New Haven, CT 06511, USA.; Department of Chemistry, The University at Buffalo, State University of New York, Buffalo, NY 14260, USA; Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA. Electronic address: davidhep@buffalo.edu.",jason.sheltzer@yale.edu.
37814061,ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results.,2023,"Nicholas, Garth; Sacher, Adrian; Wheatley-Price, Paul; Laurie, Scott A; Sausen, Mark; Bradbury, Penelope A; O'Donnell-Tormey, Jill","Ottawa Hospital Research Institute, Ottawa, ON, Canada.; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Ottawa Hospital Research Institute, Ottawa, ON, Canada.; Ottawa Hospital Research Institute, Ottawa, ON, Canada.; Personal Genome Diagnostics (LabCorp), Baltimore, MD, USA.; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Cancer Research Institute, New York, NY, USA.",jdancey@ctg.queensu.ca.
37813016,Molecular heterogeneity and co-altered genes in MET-amplified ALK-positive lung cancer: Implications for MET targeted therapy.,2023,"Kiedrowski, Lesli A","Department of Medical Affairs, Guardant Health, Inc, Center for Integrated Diagnostics, Massachusetts General Hospital, USA.",idagogo-jack@partners.org.
37792849,Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis.,2023/Nov/28,"Michelis, Fotios V; Jamy, Omer; Joseph, Jacinth; Hourigan, Christopher S","Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, Toronto, Canada.; Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL.; Methodist Healthcare Blood and Marrow Transplant Center, Memphis, TN.; Laboratory of Myeloid Malignancies, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.",None
37775370,Exploring the Role of Immunotherapy-Based Treatments for Advanced Non-Small-Cell Lung Cancer With Novel Driver Alterations.,2023,"Lorenzini, Daniele; Capone, Iolanda; Conca, Elena","Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.",teresa.beninato@istitutotumori.mi.it.
37773318,ALK fusions in the pan-cancer setting: another tumor-agnostic target?,2023/Sep/29,"Janku, Filip; Gouda, Mohamed A","Monte Rosa Therapeutics, Boston, MA, USA.; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.",rkurzrock@mcw.edu.
37768658,Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial.,2023/Nov/01,"Bedard, Philippe L; Bendell, Johanna; Oh, Do-Youn; Gil-Martin, Marta; Wu, Benjamin; Patil, Namrata S; Jin, Yanling; Hoang, Tien; Mendus, Diana; Wen, Xiaohui; Meng, Raymond","Princess Margaret Cancer Center, Toronto, Ontario, Canada.; Sarah Cannon Research Institute, Tennessee Oncology, Nashville, Tennessee.; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, South Korea.; Department of Medical Oncology, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute, Barcelona, Spain.; Clinical Pharmacology, Genentech Inc, South San Francisco, California.; Biomarkers, Genentech Inc, South San Francisco, California.; Biostatistics, F. Hoffmann-La Roche Ltd, Mississauga, Ontario, Canada.; Clinical Science, Genentech Inc, South San Francisco, California.; Clinical Science, Genentech Inc, South San Francisco, California.; Safety Science, Genentech Inc, South San Francisco, California.; Clinical Science, Genentech Inc, South San Francisco, California.",None
37768380,Effectiveness of first-line anticancer treatment may predict treatment response in further lines in stage III/IV patients with non-small cell lung cancer.,2023,"Matusikova, Magda; Hrabcova, Karolina","Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic.; Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic.",brat.kristian@fnbrno.cz.
37754495,Use of Drugs in Clinical Practice and the Associated Cost of Cancer Treatment in Adult Patients with Solid Tumors: A 10-Year Retrospective Cohort Study.,2023/Aug/30,"Carreras, Maria-Josep; Tomás-Guillén, Elena; Farriols, Anna; Renedo-Miró, Berta; Valdivia, Carolina; Vidal, Jana; Gorgas, Maria-Queralt; Monterde, Josep","Pharmacy Department, Vall d'Hebron University Hospital, E-08035 Barcelona, Spain.; Asserta Global Healthcare Solutions, Sant Quirze del Vallés, E-08192 Barcelona, Spain.; Pharmacy Department, Vall d'Hebron University Hospital, E-08035 Barcelona, Spain.; Pharmacy Department, Vall d'Hebron University Hospital, E-08035 Barcelona, Spain.; Pharmacy Department, Vall d'Hebron University Hospital, E-08035 Barcelona, Spain.; Pharmacy Department, Vall d'Hebron University Hospital, E-08035 Barcelona, Spain.; Pharmacy Department, Vall d'Hebron University Hospital, E-08035 Barcelona, Spain.; Asserta Global Healthcare Solutions, Sant Quirze del Vallés, E-08192 Barcelona, Spain.",None
37751743,Targeting METTL3 reprograms the tumor microenvironment to improve cancer immunotherapy.,2024/Apr/18,"Yu, Haisheng; Yao, Yingmeng; Zhang, Tiantian; Xiao, Xiangling; Sun, Yishuang; Xiong, Wenjun; Shi, Jie; Dai, Panpan; Xiang, Bolin; Wu, Fei; Hu, Hankun; Zhang, Haojian; He, Housheng Hansen; Zhang, Jinfang","Department of Radiation and Medical Oncology, Medical Research Institute, Frontier Science Center of Immunology and Metabolism, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan 430071, China; Taikang Center for Life and Medical Sciences, Wuhan University, Wuhan 430071, China.; Department of Radiation and Medical Oncology, Medical Research Institute, Frontier Science Center of Immunology and Metabolism, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan 430071, China; Taikang Center for Life and Medical Sciences, Wuhan University, Wuhan 430071, China.; Taikang Center for Life and Medical Sciences, Wuhan University, Wuhan 430071, China; Medical Research Institute, Frontier Science Center of Immunology and Metabolism, Wuhan University, Wuhan 430071, China.; Department of Radiation and Medical Oncology, Medical Research Institute, Frontier Science Center of Immunology and Metabolism, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan 430071, China; Taikang Center for Life and Medical Sciences, Wuhan University, Wuhan 430071, China.; Department of Radiation and Medical Oncology, Medical Research Institute, Frontier Science Center of Immunology and Metabolism, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan 430071, China; Taikang Center for Life and Medical Sciences, Wuhan University, Wuhan 430071, China.; Department of Radiation and Medical Oncology, Medical Research Institute, Frontier Science Center of Immunology and Metabolism, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan 430071, China; Taikang Center for Life and Medical Sciences, Wuhan University, Wuhan 430071, China.; Department of Radiation and Medical Oncology, Medical Research Institute, Frontier Science Center of Immunology and Metabolism, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan 430071, China; Taikang Center for Life and Medical Sciences, Wuhan University, Wuhan 430071, China.; Department of Radiation and Medical Oncology, Medical Research Institute, Frontier Science Center of Immunology and Metabolism, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan 430071, China.; Department of Radiation and Medical Oncology, Medical Research Institute, Frontier Science Center of Immunology and Metabolism, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan 430071, China; Taikang Center for Life and Medical Sciences, Wuhan University, Wuhan 430071, China.; Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, P.R.China.; Department of Pharmacy, Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, China.; Taikang Center for Life and Medical Sciences, Wuhan University, Wuhan 430071, China; Medical Research Institute, Frontier Science Center of Immunology and Metabolism, Wuhan University, Wuhan 430071, China.; Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.; Department of Radiation and Medical Oncology, Medical Research Institute, Frontier Science Center of Immunology and Metabolism, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan 430071, China; Taikang Center for Life and Medical Sciences, Wuhan University, Wuhan 430071, China. Electronic address: jinfang_zhang@whu.edu.cn.",jinfang_zhang@whu.edu.cn.
37735777,Transcriptional profiling of molecular pathways allows for the definition of robust lung squamous cell carcinoma molecular subtypes with specific vulnerabilities.,2023,"Vilariño, Noelia; Palmero, Ramón; Nadal, Ernest; Solé, Xavier","Preclinical and Experimental Research in Thoracic Tumors (PrETT), Molecular Mechanisms and Experimental Therapy in Oncology Program (Oncobell), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Spain.; Preclinical and Experimental Research in Thoracic Tumors (PrETT), Molecular Mechanisms and Experimental Therapy in Oncology Program (Oncobell), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Spain.; Preclinical and Experimental Research in Thoracic Tumors (PrETT), Molecular Mechanisms and Experimental Therapy in Oncology Program (Oncobell), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Spain.; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.",None
37731641,Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review.,2023,"Visseren-Grul, Carla; Rizzo, Maria Teresa; Puri, Tarun; Chenji, Suresh","Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, United States.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, United States.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, United States.; Eli Lilly and Company, Bengaluru, Karnataka, India.",None
37731022,Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer.,2023,"Shiraishi, Kouya; Yagishita, Shigehiro; Hamamoto, Ryuji; Motoi, Noriko; Kohno, Takashi","Division of Genome Biology, National Cancer Center Research Institute, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.; Division of Molecular Pharmacology, National Cancer Center Research Institute, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.; Division of Medical AI Research and Development, National Cancer Center Research Institute, Tokyo, 104-0045, Japan.; Division of Genome Biology, National Cancer Center Research Institute, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.; Division of Genome Biology, National Cancer Center Research Institute, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.",tatyoshi@ncc.go.jp.
37730274,CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunity.,2023,"Lim, Raymond J; Du, Yushen; Zhang, Tianhao; Crosson, William; Shabihkhani, Maryam","Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.; Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.; Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.; Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.; Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.",sdubinett@mednet.ucla.edu
37722270,Upfront liquid next-generation sequencing in treatment-naïve advanced non-small cell lung cancer patients: A prospective randomised study in the Taiwanese health system.,2023,"Yu, Chong-Jen","Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; Department of Internal Medicine, National Taiwan University Hospital, Hsin-Chu Branch, Hsinchu, Taiwan.",jyshih@ntu.edu.tw.
37720499,What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer?,2023,"Torri, Valter; Porcu, Luca","Department of Oncology, Institute of Pharmacological Research 'Mario Negri', IRCCS, Milan, Italy.; Department of Oncology, Institute of Pharmacological Research 'Mario Negri', IRCCS, Milan, Italy.",None
37710001,Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial.,2023,"Spira, Alexander I; Haura, Eric B; Sanborn, Rachel E; Cho, Eun Kyung","Virginia Cancer Specialists Research Institute, US Oncology Research, Fairfax, VA, USA.; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA.; Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea.",CBC1971@yuhs.ac.
37704166,Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1.,2023,"Garcia Campelo, R; Costantini, D; Vasseur, B","Medical Oncology Department, Complejo Hospitalario Universitario A Coruña, Biomedical Research Institute, INIBIC, A Coruña.; Medical Development Department, OSE Immunotherapeutics, Paris, France.; Medical Development Department, OSE Immunotherapeutics, Paris, France.",Benjamin.BESSE@gustaveroussy.fr.
37699333,Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression.,2023/Sep/11,"Topp, Brian G; Mayawala, Kapil; De Alwis, Dinesh P; Rubin, Eric; Snyder, Alexandra","Merck & Co., Inc, Rahway, NJ, USA. Electronic address: brian.topp@merck.com.; Merck & Co., Inc, Rahway, NJ, USA.; Merck & Co., Inc, Rahway, NJ, USA.; Merck & Co., Inc, Rahway, NJ, USA.; Merck & Co., Inc, Rahway, NJ, USA.",brian.topp@merck.com.
37686200,Detection and Monitoring of Tumor-Derived Mutations in Circulating Tumor DNA Using the UltraSEEK Lung Panel on the MassARRAY System in Metastatic Non-Small Cell Lung Cancer Patients.,2023/Aug/29,"Lozano, Nicolas; Lamy, Pierre-Jean","Institut d'Analyse Génomique Imagenome, Labosud, 34070 Montpellier, France.; Institut d'Analyse Génomique Imagenome, Labosud, 34070 Montpellier, France.",None
37677918,"A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study).",2023,"Zhao, Yuanyuan; Song, Weifeng; Wang, Zhongmin Maxwell; Li, Baiyong; Xia, Yu; Zhang, Li","Department of Medical Oncology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer, Guangzhou, China.; Akeso Biopharma, Inc., Guangzhou, China.; Akeso Biopharma, Inc., Guangzhou, China.; Akeso Biopharma, Inc., Guangzhou, China.; Akeso Biopharma, Inc., Guangzhou, China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer, Guangzhou, China. Electronic address: zhangli@sysucc.org.cn.",zhangli@sysucc.org.cn.
37675321,Developments in targeted therapy & immunotherapy-how non-small cell lung cancer management will change in the next decade: a narrative review.,2023/Aug/30,"Mok, Kevin K S","Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, China.",None
37660479,The search for therapeutic targets in lung cancer: Preclinical and human studies of carcinoembryonic antigen-related cell adhesion molecule 5 expression and its associated molecular landscape.,2023,"Scoazec, Jean-Yves","Department of Pathology and Laboratory Medicine, Gustave Roussy, Villejuif , France; Faculté de Médecine de Bicêtre, Université Paris-Saclay, Le Kremlin-Bicêtre, France.",christophe.henry@sanofi.com.
37657460,"Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study.",2023,"Zhang, Li; Greil, Richard","State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou, China.; Salzburg Cancer Research Institute-Center for Clinical Cancer and Immunology Trials (SCRI-CCCIT), Salzburg, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria; Cancer Cluster, Salzburg, Austria.",ticiana.a.leal@emory.edu.
37651020,Difficulties on the access to innovative targeted therapies for lung cancer in Spain.,2024,"Sánchez, Alfredo","Consorcio Hospital Provincial, Castellón, Spain.",vircalvo@hotmail.com.
40027286,Moving liquid biopsies to the Front-line of lung cancer treatment decisions.,2023,"Raez, Luis E; Carracedo, Carlos; Rosas, Daniel; Alvarez, Andres M","Thoracic Oncology Program, Memorial Cancer Institute, Memorial Healthcare System, Florida International University (FAU), Florida Cancer Center of Excellence, United States.; Hematology/Oncology Program, Memorial Cancer Institute, Memorial Healthcare System, United States.; Hematology/Oncology Program, Memorial Cancer Institute, Memorial Healthcare System, United States.; Oncology Research Program, Memorial Cancer Institute, Memorial Healthcare System, United States.",None
37629023,Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations.,2023/Aug/16,"Płużański, Adam","Department of Lung Cancer and Chest Tumours, The Maria Skłodowska-Curie National Research Institute of Oncology, 00-001 Warsaw, Poland.",None
37606995,Somatic rearrangements causing oncogenic ectodomain deletions of FGFR1 in squamous cell lung cancer.,2023/Nov/01,"Menon, Roopika; Heuckmann, Johannes M","DISCO Pharmaceuticals GmbH, Cologne, Germany.; DISCO Pharmaceuticals GmbH, Cologne, Germany.",None
37605861,Effectiveness of crizotinib in patients with ,2023,"Emir, Birol; Wiltshire, Robin","Pfizer Inc., 235 E 42nd St, New York, NY 10017, USA.; Pfizer Inc., 235 E 42 St, New York, NY 10017, USA.",None
37603596,Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance.,2023/Nov/01,"Alford, John; Fan, Lin; Burks, Tyler; Mansur, Leandra; Iartchouk, Oleg; Reece-Hoyes, John","Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.; Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.; Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.; Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.; Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.; Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.",None
37593227,"AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial.",2023,"Zhao, Yuanyuan; Chen, Gang; Zhuang, Wu; Zhang, Weidong; Zhang, Yu; Li, Wenting; Song, Weifeng; Wang, Zhongmin Maxwell; Li, Baiyong; Xia, Michelle; Yang, Yunpeng; Fang, Wenfeng; Huang, Yan; Zhang, Li","Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, PR China.; Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, PR China.; Department of Thoracic Medical Oncology, Fujian Provincial Cancer Hospital, Fuzhou, PR China.; Department of Respiratory and Critical Care Medicine, Hunan Provincial People's Hospital, Changsha, PR China.; Department of Oncology, Guizhou Provincial People's Hospital, Guiyang, PR China.; Akeso Biopharma, Inc., No, 6, Shennong Road, Torch Development Zone, Zhongshan, Guangdong Province, PR China.; Akeso Biopharma, Inc., No, 6, Shennong Road, Torch Development Zone, Zhongshan, Guangdong Province, PR China.; Akeso Biopharma, Inc., No, 6, Shennong Road, Torch Development Zone, Zhongshan, Guangdong Province, PR China.; Akeso Biopharma, Inc., No, 6, Shennong Road, Torch Development Zone, Zhongshan, Guangdong Province, PR China.; Akeso Biopharma, Inc., No, 6, Shennong Road, Torch Development Zone, Zhongshan, Guangdong Province, PR China.; Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, PR China.; Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, PR China.; Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, PR China.; Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, PR China.",None
37589215,Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer.,2023/Nov/02,"Arcila, Maria E; Baine, Marina K","Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.",None
40027288,"Implementation of the clinical practice of liquid biopsies for thoracic oncology the experience of the RespirERA university hospital institute (Nice, France).",2023,"Hofman, Paul","Côte d'Azur University, IHU RespirERA, FHU OncoAge, Laboratory of Clinical and Experimental Pathology, BB-0033-00025, Louis Pasteur Hospital, Nice, France.",None
37577307,A narrative review of methods for the identification of ,2023/Jul/31,"Hernandez, Susana; Conde, Esther; Alonso, Marta; Bote de Cabo, Helena; Zugazagoitia, Jon; Paz-Ares, Luis; Lopez-Rios, Fernando","Pathology Department, Hospital Universitario 12 de Octubre, Research Institute Hospital 12 de Octubre (i+12), Madrid, Spain.; Pathology Department, Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Research Institute Hospital 12 de Octubre (i+12), Ciberonc, Madrid, Spain.; Pathology Department, Hospital Universitario 12 de Octubre, Research Institute Hospital 12 de Octubre (i+12), Madrid, Spain.; Oncology Department, Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Clinical Research Unit, Research Institute Hospital 12 de Octubre (i+12)/Spanish National Cancer Research Center (CNIO), Madrid, Spain.; Oncology Department, Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Clinical Research Unit, Research Institute Hospital 12 de Octubre (i+12)/Spanish National Cancer Research Center (CNIO), Ciberonc, Madrid, Spain.; Oncology Department, Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, H12O-CNIO Lung Cancer Clinical Research Unit, Research Institute Hospital 12 de Octubre (i+12)/Spanish National Cancer Research Center (CNIO), Ciberonc, Madrid, Spain.; Pathology Department, Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Research Institute Hospital 12 de Octubre (i+12), Ciberonc, Madrid, Spain.",None
37568465,PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement.,2023/Aug/01,"Sánchez, Alfredo","Medical Oncology Department, Consorci Hospitalari Provincial de Castelló, 12002 Castelló, Spain.",None
37548831,First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1.,2023,"Li, Li; Gupta, Ravi G; Bushong, Judith","Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.",mnishio@jfcr.or.jp.
37544307,"Refractory response to entrectinib for ROS-1 rearranged NSCLC with concurrent de novo TP53 mutation showing good response to CNS lesion, but poor duration of response: A case report.",2023,"Nishio, Miho; Ushiro, Kengo","Department of Clinical Laboratory, Matsusaka Municipal Hospital, Matsusaka, Japan.; Department of Clinical Laboratory, Matsusaka Municipal Hospital, Matsusaka, Japan.",None
37542343,Network approach in liquidomics landscape.,2023/Aug/04,"Paccagnella, Elisa; De Falco, Elena","Department of Medical Surgical Sciences and Biotechnologies, Sapienza University of Rome, C.So Della Repubblica 79, 04100, Latina, Italy.; Department of Medical Surgical Sciences and Biotechnologies, Sapienza University of Rome, C.So Della Repubblica 79, 04100, Latina, Italy.",Federico_fazio@outlook.it.
37536935,Circulating immune cell dynamics as outcome predictors for immunotherapy in non-small cell lung cancer.,2023,"Marcos Rubio, Alvaro; Everaert, Celine; Van Damme, Eufra; De Preter, Katleen; Vermaelen, Karim","VIB UGent Center for Medical Biotechnology, Ghent, Belgium.; VIB UGent Center for Medical Biotechnology, Ghent, Belgium.; VIB UGent Center for Medical Biotechnology, Ghent, Belgium.; VIB UGent Center for Medical Biotechnology, Ghent, Belgium.; Cancer Research Institute Ghent (CRIG), Ghent University, Ghent, Belgium karim.vermaelen@ugent.be.",karim.vermaelen@ugent.be.
37531736,Time from immune checkpoint inhibitor to sotorasib use correlates with risk of hepatotoxicity in non-small cell lung cancer: A brief report.,2023,"Chen, Zong-Ming","Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.",dimou.anastasios@mayo.edu.
37516008,Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset.,2023,"Raez, Luis E","Memorial Healthcare System, Pembroke Pines, FL, USA.",nagasakm@hs.uci.edu.
37507657,A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer.,2023/Jul/28,"Saleh, Mansoor; Antonia, Scott; Zhao, Yumin; Gueorguieva, Ivelina; Man, Michael; Estrem, Shawn T; Liu, Jiangang; Avsar, Emin; Lin, Wen Hong; Benhadji, Karim A; Gandhi, Leena; Guba, Susan C","University of Alabama, Birmingham, AL, USA.; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.",esnadal@iconcologia.net.
37504341,Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience.,2023/Jul/08,"Banerji, Shantanu; Liu, Geoffrey","CancerCare Manitoba Research Institute, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3E 0V9, Canada.; Princess Margaret Cancer Centre, Temerty School of Medicine, University of Toronto, Toronto, ON M5G 2M9, Canada.",None
37504336,Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC.,2023/Jul/06,"Banerji, Shantanu O; Leighl, Natasha B; Sacher, Adrian; Sheffield, Brandon S; Wheatley-Price, Paul F","CancerCare Manitoba Research Institute, Department of Internal Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3E 0V9, Canada.; Department of Medicine, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON M5S 1A8, Canada.; Department of Medicine, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON M5S 1A8, Canada.; Department of Laboratory Medicine, William Osler Health System, Brampton, ON L6R 3J7, Canada.; Department of Medicine, The Ottawa Hospital Research Institute, The Ottawa Hospital, University of Ottawa, Ottawa, ON K1H 8L6, Canada.",None
37499521,A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring activating KRAS or EGFR mutations.,2023,"Sansil, Samer; Neuger, Anthony","Cancer Pharmacokinetics & Pharmacodynamics Core, Moffitt Cancer Center, 12902 Magnolia Dr., Tampa, FL 33612, USA.; Cancer Pharmacokinetics & Pharmacodynamics Core, Moffitt Cancer Center, 12902 Magnolia Dr., Tampa, FL 33612, USA.",andreas.saltos@moffitt.org.
37495171,STK11/LKB1-Deficient Phenotype Rather Than Mutation Diminishes Immunotherapy Efficacy and Represents STING/Type I Interferon/CD8,2023,"Li, Anlin; Wang, Yuanyuan; Yu, Zhixin; Tan, Zihui; He, Lina; Fu, Sha; Shi, Mengting; Du, Wei; Luo, Linfeng; Li, Zhichao; Liu, Jiaqing; Zhou, Yixin; Fang, Wenfeng; Yang, Yunpeng; Zhang, Li; Hong, Shaodong","Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China; State Key Laboratory of Oncology in South People's Republic of China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China; State Key Laboratory of Oncology in South People's Republic of China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China.; State Key Laboratory of Oncology in South People's Republic of China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China; Department of VIP Region, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China.; State Key Laboratory of Oncology in South People's Republic of China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China; Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China.; State Key Laboratory of Oncology in South People's Republic of China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China.; Department of Cellular and Molecular Diagnostics Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, People's Republic of China; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation of Sun Yat-Sen University, Guangzhou, People's Republic of China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China; State Key Laboratory of Oncology in South People's Republic of China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China; Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, People's Republic of China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China; State Key Laboratory of Oncology in South People's Republic of China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China; State Key Laboratory of Oncology in South People's Republic of China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China.; State Key Laboratory of Oncology in South People's Republic of China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China; Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China; State Key Laboratory of Oncology in South People's Republic of China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China.; State Key Laboratory of Oncology in South People's Republic of China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China; Department of VIP Region, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China; State Key Laboratory of Oncology in South People's Republic of China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China; State Key Laboratory of Oncology in South People's Republic of China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China; State Key Laboratory of Oncology in South People's Republic of China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China; State Key Laboratory of Oncology in South People's Republic of China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China. Electronic address: hongshd@sysucc.org.cn.",hongshd@sysucc.org.cn.
37490292,Association of Circulating Tumor DNA Testing Before Tissue Diagnosis With Time to Treatment Among Patients With Suspected Advanced Lung Cancer: The ACCELERATE Nonrandomized Clinical Trial.,2023/Jul/03,"García-Pardo, Miguel; Law, Jennifer H; Salvarrey, Alexandra M; Fernandes, Roxanne; Fan, Zhen J; Liu, Geoffrey; Le, Lisa W; Gunasegaran, Tharsiga; Ghumman, Noor; Shepherd, Frances A; Bradbury, Penelope A; Sacher, Adrian G; Schmid, Sabine; Corke, Lucy; Feng, Jamie; Stockley, Tracy; Pal, Prodipto; Pipinikas, Christodoulos; Howarth, Karen; Ambasager, Bana; Tsao, Ming S; Leighl, Natasha B","Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.; Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.; Pathology and Laboratory Medicine Program, University Health Network, Toronto, Ontario, Canada.; Pathology and Laboratory Medicine Program, University Health Network, Toronto, Ontario, Canada.; Inivata Ltd, Cambridge, United Kingdom.; Inivata Ltd, Cambridge, United Kingdom.; Inivata Ltd, Cambridge, United Kingdom.; Pathology and Laboratory Medicine Program, University Health Network, Toronto, Ontario, Canada.; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.",None
37480603,Efficacy of immune checkpoint inhibitor monotherapy in elderly patients with non-small-cell lung cancer.,2023,"Maeda, Yoshinobu","Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1, Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.",t-kubo@cc.okayama-u.ac.jp.
37463790,Immune suppressive microenvironment in liver metastases contributes to organ-specific response of immunotherapy in advanced non-small cell lung cancer.,2023,"Deng, Jia-Yi; Gou, Qing; Yang, Lingling; Chen, Zhi-Hong; Yang, Ming-Yi; Yang, Xiao-Rong; Yan, Hong-Hong; Wei, Xue-Wu; Liu, Jia-Qi; Su, Jian; Zhong, Wen-Zhao; Xu, Chong-Rui; Wu, Yi-Long; Zhou, Qing","Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.; Department of Interventional Radiology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.; Geneseeq Research Institute, Nanjing Geneseeq Technology Inc, Nanjing, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China gzzhouqing@126.com.",gzzhouqing@126.com.
37451931,"MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes.",2023,"Vioix, Helene; Pfeiffer, Boris M; Campden, Rhiannon I; Chen, Zhiyuan; Heeg, Bart","The Healthcare Business of Merck KGaA, Darmstadt, Germany.; The Healthcare Business of Merck KGaA, Darmstadt, Germany.; Ingress Health, A Cytel Company, Rotterdam, The Netherlands.; Ingress Health, A Cytel Company, Rotterdam, The Netherlands.; Ingress Health, A Cytel Company, Rotterdam, The Netherlands.",mazieres.j@chu-toulouse.fr.
37451404,Neoadjuvant Targeted Therapy in Resectable NSCLC: Current and Future Perspectives.,2023,"Toloza, Eric; Bara, Ilze; Kurtsikidze, Nino; Schulze, Katja; Ngiam, Celina","Department of Thoracic Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida; Department of Surgery and Department of Oncologic Sciences, University of South Florida Health Morsani College of Medicine, Tampa, Florida.; US Medical Affairs, Genentech, Inc., South San Francisco, California.; Global Product Development and Medical Affairs Oncology, F. Hoffmann-La Roche Ltd., Basel, Switzerland.; Translational Medicine, Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.; US Medical Affairs, Genentech, Inc., South San Francisco, California.",jaymoonlee@mednet.ucla.edu.
37433717,Machine learning for prediction of immunotherapeutic outcome in non-small-cell lung cancer based on circulating cytokine signatures.,2023,"Wei, Feifei; Tagami, Tomoyuki; Kouro, Taku; Igarashi, Yuka; Himuro, Hidetomo; Horaguchi, Shun; Tsuji, Kayoko; Miyagi, Yohei; Sasada, Tetsuro","Division of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, Japan tsasada@kcch.jp feifei.wei@gancen.asahi.yokohama.jp.; Research Institute for Bioscience Products and Fine Chemicals, Ajinomoto Co Inc, Kawasaki, Japan.; Division of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, Japan.; Division of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, Japan.; Division of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, Japan.; Division of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, Japan.; Division of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, Japan.; Kanagawa Cancer Center Research Institute, Yokohama, Japan.; Division of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, Japan tsasada@kcch.jp feifei.wei@gancen.asahi.yokohama.jp.",tsasada@kcch.jp
37423228,"First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study.",2023/Aug/05,"Kowalski, Dariusz; Liu, Geoffrey","Department of Lung Cancer and Thoracic Tumors, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.",sm.lee@nhs.net.
37421934,Reliability of panel-based mutational signatures for immune-checkpoint-inhibition efficacy prediction in non-small cell lung cancer.,2023,"Donker, H C; Froyen, G; Maes, B; Volders, P-J; van Es, B","Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; Global Computational Biology & Digital Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany. Electronic address: h.c.donker@umcg.nl.; Faculty of Medicine and Life Sciences - LCRC, Hasselt University, Diepenbeek, Belgium; Laboratory of Molecular Diagnostics, Dept Clinical Biology, Jessa Hospital, Hasselt, Belgium.; Faculty of Medicine and Life Sciences - LCRC, Hasselt University, Diepenbeek, Belgium; Laboratory of Molecular Diagnostics, Dept Clinical Biology, Jessa Hospital, Hasselt, Belgium. Electronic address: brigitte.maes@jessazh.be.; Laboratory of Molecular Diagnostics, Dept Clinical Biology, Jessa Hospital, Hasselt, Belgium. Electronic address: Pieter-Jan.Volders@jessazh.be.; Central Diagnostic Laboratory, University Medical Centre Utrecht, Utrecht University, Heidelberglaan 100, 3508 GA Utrecht, the Netherlands; MedxAI, Theophile de Bockstraat 77-1, 1058VA Amsterdam, the Netherlands. Electronic address: bes3@umcutrecht.nl.",bes3@umcutrecht.nl.
37418123,"SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022).",2023,"García-Campelo, Rosario; Zugazagoitia, Jon","Department of Medical Oncology, Hospital Universitario A Coruña, Health Research Institute, INIBIC, A Coruña, Spain. ma.rosario.garcia.campelo@sergas.es.; Department of Medical Oncology, Tumor Microenvironment and Immunotherapy Research Group, Hospital Universitario 12 de Octubre, Madrid, Health Research Institute Hospital Universitario 12 de Octubre (i+12), H12O-CNIO Lung Cancer Clinical Research Unit, Health Research Institute, CIBERONC, Madrid, Spain.",ma.rosario.garcia.campelo@sergas.es.
37404771,Real-world outcomes of immunotherapy with or without chemotherapy in first-line treatment of advanced non-small cell lung cancer.,2023,"Pelicon, Veronika; Knez, Lea","Department of Pharmacy, University Clinic Golnik, Golnik,  Slovenia.; Department of Pharmacy, University Clinic Golnik, Golnik,  Slovenia.",None
37393762,"Efficacy and safety of KN046, a novel bispecific antibody against PD-L1 and CTLA-4, in patients with non-small cell lung cancer who failed platinum-based chemotherapy: a phase II study.",2023,"Xu, Ting; Xu, Mo; Zhi, Lihua; Liu, Qing; Wang, Ni","Medical, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Suzhou, China.; Medical, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Suzhou, China.; Medical, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Suzhou, China.; Medical, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Suzhou, China.; Biostatistic, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Suzhou, China.",caicunzhoudr@163.com.
37391339,Pembrolizumab Alone or With Chemotherapy for 70+ Year-Old Lung Cancer Patients: A Retrospective Study.,2023,"Liersch, Stephan","Department of Pharmacy, Thoraxklinik, Heidelberg University Hospital, Heidelberg, Germany.",petros.christopoulos@med.uni-heidelberg.de.
37390764,Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results.,2023,"Graham, H; Butts, B D; Visseren-Grul, C","Eli Lilly and Company, Indianapolis, USA.; Eli Lilly and Company, Indianapolis, USA.; Eli Lilly and Company, Indianapolis, USA.",egaron@mednet.ucla.edu.
37385995,"Efficacy, safety and pharmacokinetics of Unecritinib (TQ-B3101) for patients with ROS1 positive advanced non-small cell lung cancer: a Phase I/II Trial.",2023/Jun/30,"Wang, Xicheng; Cao, Lejie; Shu, Yongqian; Cang, Shundong; Wang, Tao; Zhu, Jiajia","Department of Oncology, The First Affiliated Hospital/School of Clinical Medicine of Guangdong Pharmaceutical University, 510699, Guangzhou, China.; Department of Respiratory Medicine, The First Affiliated Hospital of the University of Science and Technology of China, Anhui Provincial Hospital, 230031, Hefei, China.; Department of Cancer Center, Jiangsu Province Hospital, 210029, Nanjing, China.; Department of Medical Oncology, Henan Province People's Hospital, 450003, Zhengzhou, China.; Biostatistics Department of Clinical Center of Research Institute, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., 222000, Nanjing, China.; Biostatistics Department of Clinical Center of Research Institute, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., 222000, Nanjing, China.",panhongming@zju.edu.cn.
37385154,A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma.,2023,"Penkov, K; Ahn, H K; Lugowska, I; Bonato, V; Damore, M A; Yang, W; Jacobs, I A; Bowers, M; Li, M; Johnson, M L","Private Healthcare Institution Clinical Hospital ""RZhD-Medicine"", St Petersburg, Russian Federation.; Division of Medical Oncology, Gachon University Gil Medical Center, Incheon, Republic of Korea.; Early Phase Clinical Trials Unit, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland.; Pfizer Inc, San Diego, USA.; Pfizer Inc, San Diego, USA.; Pfizer Inc, San Diego, USA.; Pfizer Inc, New York, USA.; Pfizer Inc, Arnold, USA.; Pfizer Inc, San Francisco, USA.; Sarah Cannon Research Institute, Tennessee Oncology PLLC, Nashville, USA. Electronic address: mjohnson@tnonc.com.",mjohnson@tnonc.com.
37380628,A landscape of response to drug combinations in non-small cell lung cancer.,2023/Jun/28,"Nair, Nishanth Ulhas; Ruppin, Eytan","Cancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.; Cancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. eytan.ruppin@nih.gov.",cyrilbenes@gmail.com.
37370772,Arising Novel Agents in Lung Cancer: Are Bispecifics and ADCs the New Paradigm?,2023/Jun/13,"Reyes, Amanda; Pharaon, Rebecca; Mohanty, Atish; Massarelli, Erminia","Department of Medical Oncology & Therapeutics Research, City of Hope National Medical Center, Duarte, CA 910102, USA.; Department of Medical Oncology & Therapeutics Research, City of Hope National Medical Center, Duarte, CA 910102, USA.; Department of Medical Oncology & Therapeutics Research, City of Hope National Medical Center, Duarte, CA 910102, USA.; Department of Medical Oncology & Therapeutics Research, City of Hope National Medical Center, Duarte, CA 910102, USA.",None
37360768,Precision oncology with selective RET inhibitor selpercatinib in ,2023,"Gouda, Mohamed A; Subbiah, Vivek","Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center. Houston, TX, USA.; Sarah Cannon Research Institute, 1100 Dr. Martin L. King Jr. Blvd. Suite 800. Nashville, TN 37203, USA.",None
37358877,Clinicogenomic factors and treatment patterns among patients with advanced non-small cell lung cancer with or without brain metastases in the United States.,2023/Nov/02,"Smyth, Emily Nash; John, Jincy; Tiu, Ramon V; Willard, Melinda Dale; Beyrer, Julie Kay; Bowman, Lee; Sheffield, Kristin M; Han, Yimei","Eli Lilly and Company, Value Evidence Outcomes - Research, Indianapolis, IN 46225, USA.; Eli Lilly and Company, Value Evidence Outcomes - Research, Indianapolis, IN 46225, USA.; Eli Lilly and Company, Value Evidence Outcomes - Research, Indianapolis, IN 46225, USA.; Eli Lilly and Company, Lilly Global Clinical Development, Indianapolis, IN 46225, USA.; Eli Lilly and Company, Value Evidence Outcomes - Research, Indianapolis, IN 46225, USA.; Eli Lilly and Company, Value Evidence Outcomes - Research, Indianapolis, IN 46225, USA.; Eli Lilly and Company, Value Evidence Outcomes - Research, Indianapolis, IN 46225, USA.; Eli Lilly and Company, Statistics RWE, Indianapolis, IN 46225, USA.",None
37352588,Uptake of novel systemic therapy: Real world patterns among adults with advanced non-small cell lung cancer.,2023,"Greenlee, Robert T; Honda, Stacey A","Marshfield Clinic Research Institute, Marshfield, WI, USA.; Hawaii Permanente Medical Group and Center for Integrated Healthcare Research, Kaiser Permanente Hawaii, Honolulu, HI, USA.",nikki.m.carroll@kp.org.
37351560,Adjustment of creatinine clearance for carboplatin dosing in Calvert's formula and clinical efficacy for lung cancer.,2023,"Yanagisawa, Kiyoshi","Division of Molecular and Cancer Medicine, Faculty of Pharmacy, Meijo University, Nagoya, Japan.",None
37343657,Somatic and germline ATM variants in non-small-cell lung cancer: Therapeutic implications.,2023,"Hernandez-Martinez, Juan-Manuel; Arrieta, Oscar","Thoracic Oncology Unit and Experimental Oncology Laboratory, Instituto Nacional de Cancerología de México (INCan), Mexico; CONACYT-Instituto Nacional de Cancerología, Mexico City, Mexico.; Thoracic Oncology Unit and Experimental Oncology Laboratory, Instituto Nacional de Cancerología de México (INCan), Mexico. Electronic address: ogar@unam.mx.",ogar@unam.mx.
37342197,Phenotyping of lymphoproliferative tumours generated in xenografts of non-small cell lung cancer.,2023,"Karasaki, Takahiro","Cancer Evolution and Genome Stability Laboratory, The Francis Crick Institute, London, United Kingdom.",None
37341856,ALK Inhibitor Treatment Patterns and Outcomes in Real-World Patients with ALK-Positive Non-Small-Cell Lung Cancer: A Retrospective Cohort Study.,2023,"Sussell, Jesse; Lin, Chia-Wei; Ogale, Sarika","Evidence for Access, Genentech Inc., South San Francisco, CA, USA.; Evidence for Access, Genentech Inc., South San Francisco, CA, USA.; Evidence for Access, Genentech Inc., South San Francisco, CA, USA.",Vivek.Rudrapatna@ucsf.edu.
37329423,"Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study.",2023,"Jen, Min-Hua","Eli Lilly and Company, Bracknell, UK.",jyshih@ntu.edu.tw.
37324065,Analysis of real-world data to investigate evolving treatment sequencing patterns in advanced non-small cell lung cancers and their impact on survival.,2023/May/30,"Liu, Zongzhi; Lee, Kyeryoung; Cohn, David; Zhang, Mingwei; Ai, Lei; Li, Minghao; Zhang, Xingming; Jun, Tomi; Higashi, Mitchell K; Pan, Qi; Oh, William; Stolovitzky, Gustavo; Schadt, Eric; Wang, Xiaoyan; Li, Shuyu D","Sema4 Mount Sinai Genomic Inc., Stamford, CT, USA.; Sema4 Mount Sinai Genomic Inc., Stamford, CT, USA.; Sema4 Mount Sinai Genomic Inc., Stamford, CT, USA.; Sema4 Mount Sinai Genomic Inc., Stamford, CT, USA.; Sema4 Mount Sinai Genomic Inc., Stamford, CT, USA.; Sema4 Mount Sinai Genomic Inc., Stamford, CT, USA.; Sema4 Mount Sinai Genomic Inc., Stamford, CT, USA.; Sema4 Mount Sinai Genomic Inc., Stamford, CT, USA.; Sema4 Mount Sinai Genomic Inc., Stamford, CT, USA.; Sema4 Mount Sinai Genomic Inc., Stamford, CT, USA.; Sema4 Mount Sinai Genomic Inc., Stamford, CT, USA.; Sema4 Mount Sinai Genomic Inc., Stamford, CT, USA.; Sema4 Mount Sinai Genomic Inc., Stamford, CT, USA.; Sema4 Mount Sinai Genomic Inc., Stamford, CT, USA.; Sema4 Mount Sinai Genomic Inc., Stamford, CT, USA.",None
37323174,Top-of-the-art cytometry as a novel tool to aid in lung cancer immunotherapy.,2023/May/31,"Mondelo-Macía, Patricia; Bernardo, David; Díaz-Peña, Roberto","Liquid Biopsy Analysis Unit, Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), Santiago de Compostela, Spain.; Mucosal Immunology Lab, Unidad de Excelencia del Instituto de Biomedicina y Genética Molecular (IBGM, Universidad de Valladolid-CSIC), Valladolid, Spain.; Fundación Pública Galega de Medicina Xenómica, Servicio Galego de Saúde (SERGAS), Grupo de Medicina Xenomica-USC, Health Research Institute of Santiago (IDIS), Santiago de Compostela, Spain.",None
37310183,Variations in Genomic Testing in Non-small Cell Lung Carcinoma: A Healthcare Professional Survey of Current Practices in the UK.,2023/Aug/03,"Desai, Ketul",Novartis Pharmaceuticals UK Limited.,None
37307681,Clinical utility of a plasma-based comprehensive genomic profiling test in patients with non-small cell lung cancer in Korea.,2023,"Ahn, Beung-Chul","Yonsei Cancer Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea; Center for Lung Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea.",cbc1971@yuhs.ac.
37306665,Understanding the patient experience and treatment benefits in patients with non-small-cell lung cancer with brain metastasis.,2023,"Vallow, Susan; Gilloteau, Isabelle; Chassot Agostinho, Andrea","Novartis Services Inc., East Hanover, New Jersey, USA.; Novartis Services Inc., East Hanover, New Jersey, USA.; Novartis Services Inc., East Hanover, New Jersey, USA.",None
37296369,Distributional Cost-Effectiveness Analysis of Treatments for Non-Small Cell Lung Cancer: An Illustration of an Aggregate Analysis and its Key Drivers.,2023,"Ramagopalan, Sreeram","Global Access, F. Hoffmann-La Roche Ltd, Grenzacherstrasse, Basel, Switzerland. s.ramagopalan@lse.ac.uk.",s.ramagopalan@lse.ac.uk.
37286305,"PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis.",2023,"McCulloch, John; Trinchieri, Giorgio; Torri, Valter","Genetics and Microbiome Core, Laboratory of Integrative Cancer Immunology, Center for Cancer Research, NCI, Bethesda, Maryland, USA.; Laboratory of Integrative Cancer Immunology, Center for Cancer Research, NIH, Bethesda, Maryland, USA.; Oncology department, Mario Negri Institute for Pharmacological Research, Milano, Lombardia, Italy.",None
37285629,Real-world outcomes in patients with KRAS G12C-mutated advanced non-small cell lung cancer treated with docetaxel in second-line or beyond.,2023,"Hsu, Hil; Younan, Diana; Suri, Gaurav; Chia, Victoria; Johnson, Melissa","Center for Observational Research, Amgen Inc., 1 Amgen Center Dr, Thousand Oaks, CA 91320, USA.; Center for Observational Research, Amgen Inc., 1 Amgen Center Dr, Thousand Oaks, CA 91320, USA.; Health Economics and Outcomes Research, Amgen Inc., 4 Uxbridge Business Park, Sanderson Road Uxbridge UB8 1DH, UK.; Center for Observational Research, Amgen Inc., 1 Amgen Center Dr, Thousand Oaks, CA 91320, USA.; Sarah Cannon Research Institute at Tennessee Oncology, Nashville, TN 37203, USA.",jhanelle.gray@moffitt.org.
37278879,"A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors.",2023,"Bauer, Todd M; Moore, Kathleen N; Hart, Lowell; Oza, Amit; Mugundu, Ganesh; Jones, Suzanne; Spigel, David","Sarah Cannon Research Institute, Nashville, TN, USA.; Sarah Cannon Research Institute, Nashville, TN, USA.; Sarah Cannon Research Institute, Fort Myers, FL, USA.; Princess Margaret Cancer Centre, Toronto, Canada.; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, AstraZeneca, Boston, MA, USA.; Sarah Cannon Research Institute, Nashville, TN, USA.; Sarah Cannon Research Institute, Nashville, TN, USA.",siqingfu@mdanderson.org.
37274265,Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage ,2023,"Szymczak, Sylwia; Szpurka, Anna M; Chao, Bo H","Loxo@Lilly, Eli Lilly and Company, Warsaw, Poland.; Loxo@Lilly, Eli Lilly and Company, Indianapolis, IN, United States.; Loxo@Lilly, Eli Lilly and Company, New York, NY, United States.",Loxo@Lilly
37268451,Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study.,2023,"Lee, Hyun-Sung","Systems Onco-Immunology Laboratory, David J Sugarbaker Division of Thoracic Surgery, Michael E DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, USA.",jwu11@mdanderson.org.
37268157,"IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications.",2023,"Herraez-Baranda, L; Liu, S N; Chan, P; Shearer-Kang, E; Liu, X; Tosti, N; Zanghi, J A; Leutgeb, B","Product Development Medical Affairs Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Clinical Pharmacology, Genentech, Inc., South San Francisco, USA.; Clinical Pharmacology, Genentech, Inc., South San Francisco, USA.; Product Safety Development, Genentech, Inc., South San Francisco, CA, USA.; Data and Statistical Sciences, Genentech, Inc., South San Francisco, CA, USA.; Product Development Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; BioAnalytical Sciences, Genentech, Inc., South San Francisco, CA, USA.; Product Development Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.",Mburotto@bradfordhill.cl.
37263673,"Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors.",2023,"Ma, Yuxiang; Xue, Jinhui; Zhao, Yuanyuan; Zhang, Yang; Huang, Yan; Yang, Yunpeng; Fang, Wenfeng; Sun, Jie; Zhang, Bangyong; Zhang, Yuhan; Xiao, Jinyuan; Zhang, Li; Zhao, Hongyun","Department of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.; Department of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.; Department of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.; Department of Clinical Medicine, Jiangsu Alphamab Biopharmaceuticals Co.,Ltd, Jiangsu, China.; Department of Clinical Operations, Jiangsu Alphamab Biopharmaceuticals Co.,Ltd, Jiangsu, China.; Department of Translational Medicine, YuceBio Technology Co., Ltd, Shenzhen, China.; Department of Translational Medicine, YuceBio Technology Co., Ltd, Shenzhen, China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China zhaohy@sysucc.org.cn zhangli@sysucc.org.cn.; Department of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China zhaohy@sysucc.org.cn zhangli@sysucc.org.cn.",zhaohy@sysucc.org.cn
37244040,The significance of co-mutations in EGFR-mutated non-small cell lung cancer: Optimizing the efficacy of targeted therapies?,2023,"Pezzuto, Federica; Hofman, Véronique; Bontoux, Christophe; Hofman, Paul","University Côte d'Azur, Laboratory of Clinical and Experimental Pathology, FHU OncoAge, BB-0033-00025, Pasteur Hospital, 30 voie romaine, 06001 Nice, France; Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova Medical School, Via A. Gabelli 61, 35121 Padova, Italy. Electronic address: federica.pezzuto@unipd.it.; University Côte d'Azur, Laboratory of Clinical and Experimental Pathology, FHU OncoAge, BB-0033-00025, Pasteur Hospital, 30 voie romaine, 06001 Nice, France.; University Côte d'Azur, Laboratory of Clinical and Experimental Pathology, FHU OncoAge, BB-0033-00025, Pasteur Hospital, 30 voie romaine, 06001 Nice, France.; University Côte d'Azur, Laboratory of Clinical and Experimental Pathology, FHU OncoAge, BB-0033-00025, Pasteur Hospital, 30 voie romaine, 06001 Nice, France. Electronic address: hofman.p@chu-nice.fr.",hofman.p@chu-nice.fr.
37243883,"Detecting ALK, ROS1, and RET fusions and the METΔex14 splicing variant in liquid biopsies of non-small-cell lung cancer patients using RNA-based techniques.",2023,"Giménez-Capitán, Ana; Robado de Lope, Lucía; Aguado, Cristina; Armiger, Noelia; Valarezo, Joselyn; Mayo-de-Las-Casas, Clara; Romero, Atocha; Molina-Vila, Miguel A","Pangaea Oncology, Laboratory of Oncology, Dexeus University Hospital, Barcelona, Spain.; Liquid Biopsy Laboratory, Biomedical Sciences Research Institute Puerta de Hierro-Majadahonda, Madrid, Spain.; Pangaea Oncology, Laboratory of Oncology, Dexeus University Hospital, Barcelona, Spain.; Pangaea Oncology, Laboratory of Oncology, Dexeus University Hospital, Barcelona, Spain.; Pangaea Oncology, Laboratory of Oncology, Dexeus University Hospital, Barcelona, Spain.; Pangaea Oncology, Laboratory of Oncology, Dexeus University Hospital, Barcelona, Spain.; Liquid Biopsy Laboratory, Biomedical Sciences Research Institute Puerta de Hierro-Majadahonda, Madrid, Spain.; Pangaea Oncology, Laboratory of Oncology, Dexeus University Hospital, Barcelona, Spain.",None
37240980,"A Real-World Experience from a Single Center (LPCE, Nice, France) Highlights the Urgent Need to Abandon Immunohistochemistry for ROS1 Rearrangement Screening of Advanced Non-Squamous Non-Small Cell Lung Cancer.",2023/May/10,"Hofman, Véronique; Goffinet, Samantha; Bontoux, Christophe; Long-Mira, Elodie; Lassalle, Sandra; Ilié, Marius; Hofman, Paul","Laboratory of Clinical and Experimental Pathology, University Côte d'Azur, FHU OncoAge, Pasteur Hospital, 06000 Nice, France.; Laboratory of Clinical and Experimental Pathology, University Côte d'Azur, FHU OncoAge, Pasteur Hospital, 06000 Nice, France.; Laboratory of Clinical and Experimental Pathology, University Côte d'Azur, FHU OncoAge, Pasteur Hospital, 06000 Nice, France.; Laboratory of Clinical and Experimental Pathology, University Côte d'Azur, FHU OncoAge, Pasteur Hospital, 06000 Nice, France.; Laboratory of Clinical and Experimental Pathology, University Côte d'Azur, FHU OncoAge, Pasteur Hospital, 06000 Nice, France.; Laboratory of Clinical and Experimental Pathology, University Côte d'Azur, FHU OncoAge, Pasteur Hospital, 06000 Nice, France.; Laboratory of Clinical and Experimental Pathology, University Côte d'Azur, FHU OncoAge, Pasteur Hospital, 06000 Nice, France.",None
37223924,Immunogenomic Landscape of Neuroendocrine Prostate Cancer.,2023/Aug/01,"Alnajar, Hussein","Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York.",None
37218137,Targeting CD73 to Overcomes Resistance to First-Generation EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.,2023,"Kim, Miso; Kim, Soyeon; Keam, Bhumsuk; Kim, Tae Min; Jeon, Yoon Kyung; Kim, Dong-Wan; Heo, Dae Seog","Cancer Research Institute, Seoul National University, Seoul, Korea.; Cancer Research Institute, Seoul National University, Seoul, Korea.; Cancer Research Institute, Seoul National University, Seoul, Korea.; Cancer Research Institute, Seoul National University, Seoul, Korea.; Cancer Research Institute, Seoul National University, Seoul, Korea.; Cancer Research Institute, Seoul National University, Seoul, Korea.; Cancer Research Institute, Seoul National University, Seoul, Korea.",None
37211905,Impact of the pretreatment prognostic nutritional index on the survival after first-line immunotherapy in non-small-cell lung cancer patients.,2023,"Toyokawa, Gouji; Wakasu, Sho; Fujimoto, Airi; Higashijima, Kodo; Takeoka, Hiroaki; Okamoto, Masaki; Yamazaki, Koji; Takeo, Sadanori","Department of Thoracic Surgery, Clinical Research Institute, National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan.; Department of Thoracic Surgery, Clinical Research Institute, National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan.; Department of Pharmacy, Clinical Research Institute, National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan.; Department of Pharmacy, National Hospital Organization Fukuoka National Hospital, Fukuoka, Japan.; Department of Respiratory Medicine, Clinical Research Institute, National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan.; Department of Respiratory Medicine, Clinical Research Institute, National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan.; Department of Thoracic Surgery, Clinical Research Institute, National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan.; Department of Thoracic Surgery, Clinical Research Institute, National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan.",None
37210008,Clinical Benefit From Immunotherapy in Patients With SCLC Is Associated With Tumor Capacity for Antigen Presentation.,2023,"Rudin, Charles M","Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Weill Cornell Medical College, New York, New York; Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: rudinc@mskcc.org.",rudinc@mskcc.org.
37195421,Improving combination therapies: targeting A2B-adenosine receptor to modulate metabolic tumor microenvironment and immunosuppression.,2023/Nov/08,"Uzhachenko, Roman V; Ryzhov, Sergey V; Feoktistov, Igor; Park, Kyungho P; Ivanova, Alla V; Kanagasabai, Thanigaivelan; Shanker, Anil","Department of Biochemistry, Cancer Biology, Neuroscience and Pharmacology, School of Medicine, Meharry Medical College, Nashville, TN, USA.; Center for Molecular Medicine, Maine Medical Center Research Institute, Scarborough, ME, USA.; Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University, Nashville, TN, USA.; Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University, Nashville, TN, USA.; Department of Biochemistry, Cancer Biology, Neuroscience and Pharmacology, School of Medicine, Meharry Medical College, Nashville, TN, USA.; Department of Biochemistry, Cancer Biology, Neuroscience and Pharmacology, School of Medicine, Meharry Medical College, Nashville, TN, USA.; Department of Biochemistry, Cancer Biology, Neuroscience and Pharmacology, School of Medicine, Meharry Medical College, Nashville, TN, USA.",None
37188764,Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors.,2023,"Himuro, Hidetomo; Igarashi, Yuka; Kouro, Taku; Higashijima, Naoko; Wei, Feifei; Horaguchi, Shun; Tsuji, Kayoko; Mano, Yasunobu; Sasada, Tetsuro","Cancer Vaccine and Immunotherapy Center, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, Japan.; Division of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, Japan.; Cancer Vaccine and Immunotherapy Center, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, Japan.; Division of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, Japan.; Cancer Vaccine and Immunotherapy Center, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, Japan.; Cancer Vaccine and Immunotherapy Center, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, Japan.; Cancer Vaccine and Immunotherapy Center, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, Japan.; Cancer Vaccine and Immunotherapy Center, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, Japan.; Cancer Vaccine and Immunotherapy Center, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, Japan. tsasada@kcch.jp.",tsasada@kcch.jp.
37186518,Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer.,2023/Jul/05,"Lee, Catherine; Jiang, Ziyue Karen; Planken, Simon; Manzuk, Lisa K; Ortiz, Roberto; Hall, Michael; Noorbehesht, Kavon; Ram, Sripad; Affolter, Timothy; Troche, Gabriel E; Ihle, Nathan T; Johnson, Theodore; Ahn, Youngwook; Kraus, Manfred; Giddabasappa, Anand","Oncology Research and Development, Pfizer Inc., Worldwide Research, Development and Medical, San Diego, California.; Global Science & Technology - Comparative Medicine, Pfizer Inc., Worldwide Research, Development and Medical, San Diego, California.; Oncology Medicinal Chemistry, Pfizer Inc., Worldwide Research, Development and Medical, San Diego, California.; Comparative Medicine, Pfizer Inc., Worldwide Research, Development and Medical, San Diego, California.; BioMedicine Design, Pfizer Inc., Worldwide Research, Development and Medical, San Diego, California.; BioMedicine Design, Pfizer Inc., Worldwide Research, Development and Medical, San Diego, California.; Global Science & Technology - Comparative Medicine, Pfizer Inc., Worldwide Research, Development and Medical, San Diego, California.; Drug Safety Research and Development Pfizer Inc., Worldwide Research, Development and Medical, San Diego, California.; Drug Safety Research and Development Pfizer Inc., Worldwide Research, Development and Medical, San Diego, California.; Oncology Research and Development, Pfizer Inc., Worldwide Research, Development and Medical, San Diego, California.; Oncology Research and Development, Pfizer Inc., Worldwide Research, Development and Medical, San Diego, California.; Medicine Design, Pfizer Inc., Worldwide Research, Development and Medical, San Diego, California.; Target Sciences, Pfizer Inc., Worldwide Research, Development and Medical, San Diego, California.; Oncology Research and Development, Pfizer Inc., Worldwide Research, Development and Medical, San Diego, California.; Global Science & Technology - Comparative Medicine, Pfizer Inc., Worldwide Research, Development and Medical, San Diego, California.",None
37183528,Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non-small-cell lung cancer in KEYNOTE-407.,2023,"Okada, Morihito; Schwarzenberger, Paul","Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.; Merck & Co., Inc., Rahway, New Jersey, USA.",None
37182602,Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification.,2023,"Lockwood, William W; Tirunagaru, Vijaya G; Doebele, Robert C","Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.; Rain Oncology Inc., Newark, California.; Rain Oncology Inc., Newark, California.",ladanyim@mskcc.org.
37173987,Early Adverse Event Derived Biomarkers in Predicting Clinical Outcomes in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy.,2023/Apr/28,"Chen, Dung-Tsa; Saltos, Andreas N; Rose, Trevor; Thompson, Zachary J; Thapa, Ram; Chiappori, Alberto; Gray, Jhanelle E","Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.; Department of Thoracic Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.; Department of Radiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.; Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.; Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.; Department of Thoracic Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.; Department of Thoracic Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.",None
37172552,"Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer.",2023,"Salifu, Idoko; Berraondo, Maria; Severson, Eric; Ramkissoon, Shakti; Vidal, Laura; Chico, Isagani; Saini, Kamal S","Labcorp Drug Development Inc., Princeton, NJ, USA. Electronic address: globalclinicalmonitors@gmail.com.; Labcorp Drug Development Inc., Princeton, NJ, USA.; Labcorp Drug Development Inc., Princeton, NJ, USA.; Labcorp Drug Development Inc., Princeton, NJ, USA; Department of Pathology, Wake Forest School of Medicine and Comprehensive Cancer Center, Winston-Salem, NC, USA.; Labcorp Drug Development Inc., Princeton, NJ, USA.; Labcorp Drug Development Inc., Princeton, NJ, USA.; Labcorp Drug Development Inc., Princeton, NJ, USA; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.",scm.salifu@gmail.com.
37169657,Regulation of dendritic cell maturation in osimertinib-treated lung adenocarcinoma patients.,2023,"Chang, Ya-Hsuan","Institute of Molecular and Genomic Medicine, National Health Research Institutes, Miaoli, Taiwan.",shwchen@ntu.edu.tw.
37158938,"First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors.",2023/May/08,"Zhao, Yuanyuan; Ma, Yuxiang; Ba, Yi; Kang, Xiaoyan; Xue, Shilin; Yang, Guihong; Yang, Yingying; Zhang, Li; Zhao, Hongyun","Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, No. 651 Dongfeng East Road, Guangzhou, 510060, China.; Department of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, No. 651 Dongfeng East Road, Guangzhou, 510060, China.; Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China.; Clinical Research Center, Qilu Pharmaceutical Co., Ltd., Jinan, 250000, China.; Clinical Research Center, Qilu Pharmaceutical Co., Ltd., Jinan, 250000, China.; Department of Clinical Pharmacology, Qilu Pharmaceutical Co., Ltd., Jinan, 250000, China.; Department of Non-Clinical, Qilu Pharmaceutical Co., Ltd., Jinan, 250001, China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, No. 651 Dongfeng East Road, Guangzhou, 510060, China. zhangli@sysucc.org.cn.; Department of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, No. 651 Dongfeng East Road, Guangzhou, 510060, China. zhaohy@sysucc.org.cn.",zhaohy@sysucc.org.cn.
37156009,Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience.,2023/Nov/02,"Zhong, Linda L; Akhmedzhanov, Fechukwu O; Zarifa, Abdulrazzak; Albittar, Aya A; Yang, Vincent; Naing, Aung","Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.",None
37147298,Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma.,2023/May/05,"Petrova, Zaritza O; Wu, Megan A; Smith, Courtney M; Pavlick, Dean; Goldsmith, Kelly C; Lemmon, Mark A","Department of Pharmacology, Yale University School of Medicine, New Haven, CT, USA.; Department of Pharmacology, Yale University School of Medicine, New Haven, CT, USA.; Department of Pharmacology, Yale University School of Medicine, New Haven, CT, USA.; Foundation Medicine, Inc, Cambridge, MA, USA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA.; Department of Pharmacology, Yale University School of Medicine, New Haven, CT, USA. mark.lemmon@yale.edu.",mosse@chop.edu.
37137552,Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs.,2023,"Selig, Wendy; Ebbinghaus, Scot","WSCollaborative, McLean, Virginia, USA.; Merck & Co Inc, Kenilworth, New Jersey, USA.",tian.zhang@utsouthwestern.edu.
37129893,Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy.,2023/May/01,"Ben-Shachar, Rotem; Gao, Yinjie; Hyun, Seung Won; Rivers, Zachary; Epstein, Carrie; Kaneva, Kristiyana; Sangli, Chithra; Nimeiri, Halla","Tempus Labs, Chicago, Illinois.; Tempus Labs, Chicago, Illinois.; Tempus Labs, Chicago, Illinois.; Tempus Labs, Chicago, Illinois.; Tempus Labs, Chicago, Illinois.; Tempus Labs, Chicago, Illinois.; Tempus Labs, Chicago, Illinois.; Tempus Labs, Chicago, Illinois.",None
37096188,Gumarontinib in patients with non-small-cell lung cancer harbouring ,2023,"Shu, Yongqian; Li, Fugen; Li, Meng; Wu, Qiuxia; Zhou, Jun; Sun, Minghui","Oncology Department, Jiangsu Province Hospital, Nanjing, China.; Clinical Science Department, Haihe Biopharma Co., Ltd, Shanghai, China.; Biostatistic and Data Science, Haihe Biopharma Co., Ltd, Shanghai, China.; Clinical Science Department, Haihe Biopharma Co., Ltd, Shanghai, China.; Clinical Science Department, Haihe Biopharma Co., Ltd, Shanghai, China.; Clinical Science Department, Haihe Biopharma Co., Ltd, Shanghai, China.",None
37086716,Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer.,2023/May/08,"Swanton, Charles; Asselin-Labat, Marie-Liesse","Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK; Cancer Evolution and Genome Instability Laboratory, Francis Crick Institute, London, UK; University College London Hospitals, London, UK.; Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia; Department of Medical Biology, the University of Melbourne, Parkville, VIC, Australia. Electronic address: labat@wehi.edu.au.",labat@wehi.edu.au.
37085581,Using genomic scars to select immunotherapy beneficiaries in advanced non-small cell lung cancer.,2023/Apr/21,"van Es, B","Central Diagnostic Laboratory, University Medical Centre Utrecht, Utrecht University, Heidelberglaan 100, 3508 GA, Utrecht, The Netherlands. bes3@umcutrecht.nl.",bes3@umcutrecht.nl.
37078460,Genomic and immune characteristics of HER2-mutated non-small-cell lung cancer and response to immune checkpoint inhibitor-based therapy.,2023,"Tu, Hai-Yan; Yin, Kai; Zhao, Xiaotian; Ke, E-E; Wu, Si-Pei; Li, Yang-Si; Zheng, Mei-Mei; Liu, Si-Yang Maggie; Xu, Chong-Rui; Sun, Yue-Li; Lin, Jia-Xin; Bai, Xiao-Yan; Zhang, Yi-Chen; Zhou, Qing; Yang, Jin-Ji; Zhong, Wen-Zhao; Wang, Bing-Chao; Zhu, Dongqin; Yang, Lingling; Ou, Qiuxiang; Wu, Yi-Long","Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.; Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.; Guangdong Lung Cancer Institute, Medical Research Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.; Department of Hematology, First Affiliated Hospital, Institute of Hematology, School of Medicine, Key Laboratory for Regenerative Medicine of Ministry of Education, Jinan University, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.; Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., China.; Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., China.; Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.",None
37076834,Improved uptake and survival with systemic treatments for metastatic non-small cell lung cancer: younger versus older adults.,2023/Apr/19,"Moore, Sara","The Ottawa Hospital Cancer Centre, Ottawa Hospital Research Institute, Ottawa, ON, Canada.",Bonnie.Leung@bccancer.bc.ca.
37069698,Emerging evidence and treatment paradigm of non-small cell lung cancer.,2023/Apr/17,"Zheng, Mei-Mei; Pan, Yi; Liu, Si-Yang; Wu, Yi-Long","Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, 106 Zhongshan Er Road, Guangzhou, 510080, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, 106 Zhongshan Er Road, Guangzhou, 510080, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, 106 Zhongshan Er Road, Guangzhou, 510080, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, 106 Zhongshan Er Road, Guangzhou, 510080, China. syylwu@live.cn.",syylwu@live.cn.
37069542,Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting.,2023/Apr/17,"Julian, Cristina; Pal, Navdeep; Gershon, Anda; Evangelista, Marie; Purkey, Hans; Lambert, Peter; Shi, Zhen; Zhang, Qing","1 DNA Way, Genentech, Inc, South San Francisco, CA, 94080, USA.; 1 DNA Way, Genentech, Inc, South San Francisco, CA, 94080, USA.; 1 DNA Way, Genentech, Inc, South San Francisco, CA, 94080, USA.; 1 DNA Way, Genentech, Inc, South San Francisco, CA, 94080, USA.; 1 DNA Way, Genentech, Inc, South San Francisco, CA, 94080, USA.; 1 DNA Way, Genentech, Inc, South San Francisco, CA, 94080, USA.; 1 DNA Way, Genentech, Inc, South San Francisco, CA, 94080, USA. shi.zhen@gene.com.; 1 DNA Way, Genentech, Inc, South San Francisco, CA, 94080, USA. zhangq47@gene.com.",zhangq47@gene.com.
37059804,Single targeting of MET in EGFR-mutated and MET-amplified non-small cell lung cancer.,2023,"Choi, Yu-Ra; Kang, Eun Hye; Kim, Sunshin; Han, Ji-Youn; Lee, Youngjoo","Research Institute, National Cancer Center, Goyang, Republic of Korea.; Research Institute, National Cancer Center, Goyang, Republic of Korea.; Research Institute, National Cancer Center, Goyang, Republic of Korea.; Research Institute, National Cancer Center, Goyang, Republic of Korea.; Research Institute, National Cancer Center, Goyang, Republic of Korea. yjlee@ncc.re.kr.",yjlee@ncc.re.kr.
37057117,Transformation of ,2023/Mar/31,"Zhang, Junling; Hofman, Paul; Huang, Mengli","Medical Department, 3D Medicines Inc., Shanghai, China.; Laboratory of Clinical and Experimental Pathology, FHU OncoAge, Pasteur Hospital, BB-0033-00025, CHU Nice, University Côte d'Azur, Nice, France.; Medical Department, 3D Medicines Inc., Shanghai, China.",None
37055640,Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA.,2023,"Pich, Oriol; Watkins, Thomas B K; Cook, Daniel E","Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.",Charles.Swanton@crick.ac.uk.
37046096,The evolution of lung cancer and impact of subclonal selection in TRACERx.,2023,"Frankell, Alexander M; Dietzen, Michelle; Al Bakir, Maise; Lim, Emilia L; Karasaki, Takahiro; Ward, Sophia; Colliver, Emma; Huebner, Ariana; Hill, Mark S; Grigoriadis, Kristiana; Moore, David A; Pich, Oriol; Watkins, Thomas B K; Cook, Daniel E; Wilson, Gareth A; Bailey, Chris; Angelova, Mihaela; Biswas, Dhruva; Rosenthal, Rachel; Puttick, Clare; Lee, Claudia; Russell, Peter; Birkbak, Nicolai J; Hiley, Crispin T; Swanton, Charles","Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Princess Alexandra Hospital, The Princess Alexandra Hospital NHS Trust, Harlow, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK. charles.swanton@crick.ac.uk.",charles.swanton@crick.ac.uk.
37046095,The evolution of non-small cell lung cancer metastases in TRACERx.,2023,"Watkins, Thomas B K; Pich, Oriol; Rowan, Andrew; Colliver, Emma; Hill, Mark S; Cook, Daniel E; Wilson, Gareth A; Van Loo, Peter","Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Genomics Laboratory, The Francis Crick Institute, London, UK.",Charles.Swanton@crick.ac.uk.
37046094,Antibodies against endogenous retroviruses promote lung cancer immunotherapy.,2023,"Ng, Kevin W; Boumelha, Jesse; Enfield, Katey S S; Almagro, Jorge; Pich, Oriol; Karasaki, Takahiro; Moore, David A; Young, George; Molina-Arcas, Miriam; de Carné Trécesson, Sophie; Anastasiou, Panayiotis; Fendler, Annika; Au, Lewis; Shepherd, Scott T C; Puttick, Clare; Watkins, Thomas B K; Faulkner, Nikhil; Attig, Jan; Ward, Sophia; Frankell, Alexander M; Al Bakir, Maise; Lim, Emilia L; Hill, Mark S; Wilson, Gareth A; Cook, Daniel E; Birkbak, Nicolai J; Behrens, Axel; Hiley, Crispin T; Turajlic, Samra; Swanton, Charles; Downward, Julian; Kassiotis, George","Retroviral Immunology Laboratory, The Francis Crick Institute, London, UK.; Oncogene Biology Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Adult Stem Cell Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Retroviral Immunology Laboratory, The Francis Crick Institute, London, UK.; Oncogene Biology Laboratory, The Francis Crick Institute, London, UK.; Oncogene Biology Laboratory, The Francis Crick Institute, London, UK.; Oncogene Biology Laboratory, The Francis Crick Institute, London, UK.; Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK.; Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK.; Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Retroviral Immunology Laboratory, The Francis Crick Institute, London, UK.; Retroviral Immunology Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Adult Stem Cell Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK. charles.swanton@crick.ac.uk.; Oncogene Biology Laboratory, The Francis Crick Institute, London, UK. julian.downward@crick.ac.uk.; Retroviral Immunology Laboratory, The Francis Crick Institute, London, UK. george.kassiotis@crick.ac.uk.",george.kassiotis@crick.ac.uk.
37046093,Genomic-transcriptomic evolution in lung cancer and metastasis.,2023,"Hill, Mark S; Demeulemeester, Jonas; Larose Cadieux, Elizabeth; Rowan, Andrew; Pich, Oriol; Colliver, Emma; Castignani, Carla; Watkins, Thomas B K; Cook, Daniel E; Rosenthal, Rachel; Wilson, Gareth A; de Carné Trécesson, Sophie; Van Loo, Peter","Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute and University College London Cancer Institute, London, UK.; Cancer Genomics Laboratory, The Francis Crick Institute, London, UK.; Cancer Genomics Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute and University College London Cancer Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute and University College London Cancer Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute and University College London Cancer Institute, London, UK.; Cancer Genomics Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute and University College London Cancer Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute and University College London Cancer Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute and University College London Cancer Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute and University College London Cancer Institute, London, UK.; Oncogene Biology Laboratory, The Francis Crick Institute, London, UK.; Cancer Genomics Laboratory, The Francis Crick Institute, London, UK.",nicholas.mcgranahan.10@ucl.ac.uk.
37045997,Body composition and lung cancer-associated cachexia in TRACERx.,2023,"Collins, Susie; Popuri, Karteek","Early Clinical Development, Pfizer UK Ltd, Cambridge, UK.; Department of Computer Science, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Burnaby, Canada.",Charles.swanton@crick.ac.uk.
37025758,Phase II multicenter trial combining nivolumab and radiosurgery for NSCLC and RCC brain metastases.,2023,"Keshavarzi, Sareh","Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.",None
37025260,A transcriptomics approach to expand therapeutic options and optimize clinical trials in oncology.,2023,"Zhang, Baolin","Office of Biotechnology Products (OBP), Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA), Silver Spring, MA, USA.",None
37024582,Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer.,2023,"Rizvi, Naiyer","Synthekine, Inc., Menlo Park, CA, USA.",jgainor@mgh.harvard.edu.
37021770,Cost-effectiveness of adjuvant atezolizumab for patients with stage II-IIIA PD-L1+ non-small-cell lung cancer.,2023,"Ogale, Sarika; Jovanoski, Nick; Johnson, Ann; Nguyen, Caroline; Bhagwakar, Jan; Lee, Janet S","Genentech Inc, South San Francisco, CA 94080, USA.; F. Hoffmann-La Roche Ltd, 4070 Basel, Switzerland.; Genentech Inc, South San Francisco, CA 94080, USA.; Genentech Inc, South San Francisco, CA 94080, USA.; Genentech Inc, South San Francisco, CA 94080, USA.; Genentech Inc, South San Francisco, CA 94080, USA.",None
37017806,Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study.,2023,"Arrieta, Oscar; Rojas, Leonardo; Zatarain-Barrón, Zyanya Lucia; Malapelle, Umberto; Rosell, Rafael","Thoracic Oncology Unit and Personalized Oncology Laboratory, National Cancer Institute (INCan), México City, Mexico.; Thoracic Oncology Unit and Personalized Oncology Laboratory, National Cancer Institute (INCan), México City, Mexico.; Thoracic Oncology Unit and Personalized Oncology Laboratory, National Cancer Institute (INCan), México City, Mexico.; Predictive Molecular Pathology Laboratory, Department of Public Health, University Federico II of Naples, Naples, Italy.; Cancer Biology and Precision Medicine Program, Germans Trias i Pujol Research Institute (IGTP)/Dr. Rosell Oncology Institute (IOR) Quirón-Dexeus University Institute, Barcelona, Spain.",acardona@fctic.org.
37016126,"First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors.",2023,"Bendell, Johanna; Wise-Draper, Trisha","Sarah Cannon Research Institute, Nashville, TN, USA. Johanna.bendell@roche.com.; University of Cincinnati Cancer Center, Cincinnati, OH, USA.",Johanna.bendell@roche.com.
37003208,Real-world treatment patterns and outcomes of patients with metastatic nonsquamous non-small cell lung cancer after progression on standard-of-care therapy in the United States.,2023,"Divan, Hozefa A; Krishna, Ashok","Sanofi, Inc., 450 Water Street, Cambridge, MA 02142, USA. Electronic address: hozefa.divan@sanofi.com.; Sanofi, Inc., 450 Water Street, Cambridge, MA 02142, USA.",hozefa.divan@sanofi.com.
37001526,Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade.,2023/Apr/10,"Sauter, Jennifer L; Baine, Marina K; Gigoux, Mathieu; Wolchok, Jedd D; Merghoub, Taha; Chow, Andrew","Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA; Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: chowa1@mskcc.org.",satpathy@stanford.edu.
36997937,Septin-3 autoimmunity in patients with paraneoplastic cerebellar ataxia.,2023/Mar/30,"Borowski, Kathrin; Teegen, Bianca; Ruprecht, Klemens","Clinical Immunological Laboratory Prof. Dr. med. Winfried Stöcker, Lübeck, Germany.; Clinical Immunological Laboratory Prof. Dr. med. Winfried Stöcker, Lübeck, Germany.; Department of Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.",sven.jarius@med.uni-heidelberg.de.
36996322,"Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung Cancers.",2023/Aug/15,"Rajappa, Senthil","Basavatarakam Indo-American Cancer Hospital and Research Institute, Nandi Nagar, Banjara Hills, Hyderabad, Telangana, India.",None
36983409,Nivolumab or Atezolizumab in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer? A Prognostic Index Based on Data from Daily Practice.,2023/Mar/21,"Knetki-Wróblewska, Magdalena; Tabor, Sylwia; Piórek, Aleksandra; Płużański, Adam; Winiarczyk, Kinga; Zaborowska-Szmit, Magdalena; Zajda, Katarzyna; Kowalski, Dariusz M; Krzakowski, Maciej","Department of Lung Cancer and Chest Tumours, The Maria Skłodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.; Department of Lung Cancer and Chest Tumours, The Maria Skłodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.; Department of Lung Cancer and Chest Tumours, The Maria Skłodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.; Department of Lung Cancer and Chest Tumours, The Maria Skłodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.; Department of Lung Cancer and Chest Tumours, The Maria Skłodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.; Department of Lung Cancer and Chest Tumours, The Maria Skłodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.; Department of Lung Cancer and Chest Tumours, The Maria Skłodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.; Department of Lung Cancer and Chest Tumours, The Maria Skłodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.; Department of Lung Cancer and Chest Tumours, The Maria Skłodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.",None
36975443,"Immune Checkpoint Inhibitors-Associated Thrombosis: Incidence, Risk Factors and Management.",2023/Mar/04,"Wang, Tzu-Fei; Carrier, Marc","Department of Medicine, University of Ottawa at The Ottawa Hospital and Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada.; Department of Medicine, University of Ottawa at The Ottawa Hospital and Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada.",None
36969063,"Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC).",2023,"Meertens, Marinda; Ter Heine, Rob; Touw, Daan J; van Boven, Job F M; Croes, Sander; Huitema, Alwin D R; Steeghs, Neeltje","Department of Pharmacy and Pharmacology, Netherlands Cancer Institute, Amsterdam, Netherlands.; Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center Nijmegen, Nijmegen, Netherlands.; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.; Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Center, CARIM School for Cardiovascular disease, Maastricht, Netherlands.; Department of Pharmacy and Pharmacology, Netherlands Cancer Institute, Amsterdam, Netherlands.; Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.",None
36963241,Biomarkers of response to immunotherapy in early stage non-small cell lung cancer.,2023,"Roulleaux Dugage, Matthieu; Albarrán-Artahona, Víctor; Chaput, Nathalie; Mezquita, Laura","Department of Oncology, Hôpital Européen Georges Pompidou, AP-HP, Université Paris Cité, Paris, France; Laboratoire D'Immunomonitoring en Oncologie, INSERM US23, CNRS UMS 3655, Gustave Roussy, Villejuif, Île-de-France, France.; Medical Oncology Department, Hospital Clinic de Barcelona, Spain; Laboratory of Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona, Spain.; Laboratoire D'Immunomonitoring en Oncologie, INSERM US23, CNRS UMS 3655, Gustave Roussy, Villejuif, Île-de-France, France.; Medical Oncology Department, Hospital Clinic de Barcelona, Spain; Laboratory of Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona, Spain; Department of Medicine, University of Barcelona, Barcelona, Spain.",edouard.auclin@aphp.fr.
36961477,Supporting Biomarker-Driven Therapies in Oncology: A Genomic Testing Cost Calculator.,2023/May/08,"Cuffel, Brian; Paracha, Noman; Vail, Eric; Goodman, Clifford; Sullivan, Sean D","Bayer Pharmaceuticals, Basel, Switzerland.; Bayer Pharmaceuticals, Basel, Switzerland.; Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, CA, USA.; The Lewin Group, Inc., Falls Church, VA, USA.; CHOICE Institute, Department of Pharmacy, School of Pharmacy, University of Washington, Seattle, WA, USA.",None
36958133,Next-generation sequencing of non-small cell lung cancer at a Quebec health care cancer centre.,2023,"Sorin, Mark; Huynh, Caroline; Witkowski, Leora; Zogopoulos, George; Wang, Yifan; Wang, Hangjun; Spicer, Jonathan; Walsh, Logan A; Rayes, Roni; Rouleau, Guy; Spatz, Alan; Corredor, Andrea Liliam Gomez","Rosalind and Morris Goodman Cancer Research Institute, McGill University, Canada; Department of Human Genetics, McGill University, Canada.; Rosalind and Morris Goodman Cancer Research Institute, McGill University, Canada.; Department of Human Genetics, McGill University, Canada; Core Molecular Diagnostic Laboratory, McGill University Health Centre, Canada.; Rosalind and Morris Goodman Cancer Research Institute, McGill University, Canada; Department of Surgery, McGill University, Canada.; Rosalind and Morris Goodman Cancer Research Institute, McGill University, Canada; Department of Surgery, McGill University, Canada.; McGill University Optilab Network, Canada.; Rosalind and Morris Goodman Cancer Research Institute, McGill University, Canada; Department of Surgery, McGill University, Canada.; Rosalind and Morris Goodman Cancer Research Institute, McGill University, Canada; Department of Human Genetics, McGill University, Canada.; Rosalind and Morris Goodman Cancer Research Institute, McGill University, Canada.; Department of Human Genetics, McGill University, Canada; Core Molecular Diagnostic Laboratory, McGill University Health Centre, Canada; McGill University Optilab Network, Canada.; McGill University Optilab Network, Canada.; Department of Pathology, McGill University Health Centre, Glen Site, 1001 Boulevard Décarie, Montreal, QC H4A 3J1, Canada; Core Molecular Diagnostic Laboratory, McGill University Health Centre, Canada; McGill University Optilab Network, Canada.",pierre.o.fiset@mcgill.ca.
36947997,Cost-effectiveness analysis of adjuvant atezolizumab in stage II-IIIA non-small cell lung cancer expressing ≥50% PD-L1: A United Kingdom health care perspective.,2023,"Yip, Chui-Ying; Abogunrin, Seye; Belleli, Rossella; Di Maio, Danilo; Rouse, Peter; Jovanoski, Nick","Roche Products Ltd, Welwyn Garden City, United Kingdom. Electronic address: chui-ying.yip@roche.com.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Roche Products Ltd, Welwyn Garden City, United Kingdom.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.",chui-ying.yip@roche.com.
36947734,Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in ,2023/May/10,"Rutkowski, Piotr; McKean, Meredith; Gaur, Anil; Evans, Helen; Basu, Sumit","Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.; Sarah Cannon Research Institute at Tennessee Oncology, Nashville, TN.; Novartis Healthcare Private Limited, Hyderabad, India.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharmaceuticals Corporation, East Hanover, NJ.",None
36944282,Use of radiation therapy among patients with Extensive-stage Small-cell lung cancer receiving Immunotherapy: Canadian consensus recommendations.,2023,"Sun, Alexander; Greenland, Jonathan; Liu, Geoffrey","Princess Margaret Cancer Centre, 700 University Avenue, Toronto, ON M5G 1Z5, Canada. Electronic address: alex.sun@rmp.uhn.ca.; Eastern Health, 300 Prince Philip Drive, St. John's, NL A1B 3V6, Canada. Electronic address: jonathan.greenland@easternhealth.ca.; Princess Margaret Cancer Centre, University Health Network, 610 University Avenue, Toronto, ON M5G 2M9, Canada. Electronic address: geoffrey.liu@uhn.ca.",geoffrey.liu@uhn.ca.
36940614,"Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectives.",2023,"Kaiser, Rolf","Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany; Institute of Pharmacology, Johannes Gutenberg-University Mainz, Mainz, Germany.",dr.martin.reck@web.de.
36929402,"Trends in Survival Rates of Non-Small Cell Lung Cancer With Use of Molecular Testing and Targeted Therapy in Korea, 2010-2020.",2023/Mar/01,"Kim, Kyunga","Biomedical Statistics Center, Research Institute for Future Medicine, Samsung Medical Center, Seoul, Republic of Korea.",None
36927889,Predicting EGFR mutational status from pathology images using a real-world dataset.,2023/Mar/16,"Pao, James J; Biggs, Mikayla; Duncan, Daniel; Lin, Douglas I; Davis, Richard; Huang, Richard S P; Ferguson, Donna; Janovitz, Tyler; Hiemenz, Matthew C; Eddy, Nathanial R; Lehnert, Erik; Cabili, Moran N; Frampton, Garrett M; Hegde, Priti S; Albacker, Lee A","Foundation Medicine Inc., 150 Second Street, Cambridge, MA, USA.; Foundation Medicine Inc., 150 Second Street, Cambridge, MA, USA.; Foundation Medicine Inc., 150 Second Street, Cambridge, MA, USA.; Foundation Medicine Inc., 150 Second Street, Cambridge, MA, USA.; Foundation Medicine Inc., 150 Second Street, Cambridge, MA, USA.; Foundation Medicine Inc., 150 Second Street, Cambridge, MA, USA.; Foundation Medicine Inc., 150 Second Street, Cambridge, MA, USA.; Foundation Medicine Inc., 150 Second Street, Cambridge, MA, USA.; Foundation Medicine Inc., 150 Second Street, Cambridge, MA, USA.; Foundation Medicine Inc., 150 Second Street, Cambridge, MA, USA.; Foundation Medicine Inc., 150 Second Street, Cambridge, MA, USA.; Foundation Medicine Inc., 150 Second Street, Cambridge, MA, USA.; Foundation Medicine Inc., 150 Second Street, Cambridge, MA, USA.; Foundation Medicine Inc., 150 Second Street, Cambridge, MA, USA.; Foundation Medicine Inc., 150 Second Street, Cambridge, MA, USA. lalbacker@foundationmedicine.com.",lalbacker@foundationmedicine.com.
36925916,Baseline risk factors associated with immune related adverse events and atezolizumab.,2023,"Maiya, Vidya","Product Development (PD), Genentech, Inc., South San Francisco, CA, United States.",None
36922348,Differential Chemoproteomics Reveals MARK2/3 as Cell Migration-Relevant Targets of the ALK Inhibitor Brigatinib.,2023/Jun/01,"Hu, Qianqian; Liao, Yi; Cao, Jessica; Fang, Bin; Yun, Sang Y; Kinose, Fumi; Haura, Eric B; Lawrence, Harshani R; Rix, Uwe","Department of Drug Discovery, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, 33612, USA.; Department of Drug Discovery, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, 33612, USA.; Department of Drug Discovery, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, 33612, USA.; Proteomics and Metabolomics Core, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, 33612, USA.; Chemical Biology Core (Chemistry Unit), H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, 33612, USA.; Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, 33612, USA.; Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, 33612, USA.; Chemical Biology Core (Chemistry Unit), H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, 33612, USA.; Department of Drug Discovery, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, 33612, USA.",None
36900371,"Treatment Patterns, Testing Practices, and Outcomes in Patients with ",2023/Mar/03,"Pluzanski, Adam; Samborska, Agnieszka; Krzakowski, Maciej","Lung Cancer and Chest Tumors Department, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.; AstraZeneca Pharma Poland Sp.zo.o., 02-676 Warsaw, Poland.; Lung Cancer and Chest Tumors Department, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.",None
36872130,"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.",2023,"Mok, T S","Department of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China.",None
36866788,Exploratory analysis of immunochemotherapy compared to chemotherapy after EGFR-TKI in non-small cell lung cancer patients with EGFR mutation: A multicenter retrospective study.,2023,"Kobe, Hiroshi; Yokoyama, Toshihide","Department of Respiratory Medicine, Ohara Healthcare Foundation, Kurashiki Central Hospital, Okayama, Japan.; Department of Respiratory Medicine, Ohara Healthcare Foundation, Kurashiki Central Hospital, Okayama, Japan.",None
36866462,Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay.,2023/Apr/06,"Danziger, Natalie; Sokol, Ethan S; Graf, Ryon P; Hiemenz, Matthew C; Maule, Jake; Parimi, Vamsi; Ross, Jeffrey S; Huang, Richard S P","Foundation Medicine, Inc., Cambridge, MA, USA.; Foundation Medicine, Inc., Cambridge, MA, USA.; Foundation Medicine, Inc., Cambridge, MA, USA.; Foundation Medicine, Inc., Cambridge, MA, USA.; Foundation Medicine, Inc., Cambridge, MA, USA.; Foundation Medicine, Inc., Cambridge, MA, USA.; Foundation Medicine, Inc., Cambridge, MA, USA.; Foundation Medicine, Inc., Cambridge, MA, USA.",None
36863067,Budget Impact Analysis of Comprehensive Genomic Profiling in Advanced Non-Small Cell Lung Cancer in Taiwan.,2023,"Tsai, Yi-Ling","Department of Biomedical Science, Chang Gung University, TaoYuan, Taiwan; Roche Product, Inc, Taipei, Taiwan.",cjchang@mail.cgu.edu.tw.
36852704,Dynamic changes in circulating tumor DNA assessed by shallow whole-genome sequencing associate with clinical efficacy of checkpoint inhibitors in NSCLC.,2023,"Vivancos, Ana; Sansó, Miriam","Cancer Genomics Laboratory, Vall d'Hebron Institut d'Oncologia (VHIO), Barcelona, Spain.; Balearic Islands Health Research Institute (IdISBa), Palma de Mallorca, Spain.",None
36842467,MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy.,2023,"Berz, David; Waterhouse, David M; Olson, Peter; Latven, Lisa; Yan, Xiaohong; Shazer, Ronald","Department of Cellular Therapeutics, Beverly Hills Cancer Center, Beverly Hills, California; Current Affiliation: Valkyrie Clinical Trials, Los Angeles, California.; US Oncology Network, The Woodlands, Texas; Department of Clinical Research, Oncology Hematology Care, Cincinnati, Ohio; Current affiliation: Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center, Milford, Massachusetts.; Mirati Therapeutics, Inc., San Diego, California.; Mirati Therapeutics, Inc., San Diego, California.; Mirati Therapeutics, Inc., San Diego, California.; Mirati Therapeutics, Inc., San Diego, California.",kai.he@osumc.edu.
36841727,A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer.,2023,"Sacher, Adrian","Princess Margaret Cancer Centre, Toronto, Ontario, Canada.",wade.t.iams@vumc.org.
36831447,"Upfront Advanced Radiotherapy and New Drugs for NSCLC Patients with Synchronous Brain Metastases: Is the Juice Worth the Squeeze? A Real-World Analysis from Lombardy, Italy.",2023/Feb/09,"Franchi, Matteo","National Centre for Healthcare Research and Pharmacoepidemiology, University of Milano-Bicocca, 20126 Milan, Italy.",None
36826141,Cost Savings of Expedited Care with Upfront Next-Generation Sequencing Testing versus Single-Gene Testing among Patients with Metastatic Non-Small Cell Lung Cancer Based on Current Canadian Practices.,2023/Feb/15,"Eaton, Kiefer; Emond, Bruno; Lafeuille, Marie-Hélène; Hilts, Annalise; Lefebvre, Patrick; Morrison, Laura; Stevens, Andrea L; Ewara, Emmanuel M","Janssen, Inc., Toronto, ON M3C 1L9, Canada.; Analysis Group, Inc., Montréal, QC H3B 0G7, Canada.; Analysis Group, Inc., Montréal, QC H3B 0G7, Canada.; Analysis Group, Inc., Montréal, QC H3B 0G7, Canada.; Analysis Group, Inc., Montréal, QC H3B 0G7, Canada.; Analysis Group, Inc., Montréal, QC H3B 0G7, Canada.; Janssen Global Services, Inc., Raritan, NJ 08869, USA.; Janssen, Inc., Toronto, ON M3C 1L9, Canada.",None
36823150,Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial.,2023/Feb/24,"Zhong, Wen-Zhao; Yan, Hong-Hong; Yang, Xue-Ning; Qiao, Gui-Bin; Cheng, Ying; Liao, Ri-Qiang; Yang, Jin-Ji; Zhang, Xu-Chao; Liu, Si-Yang; Zhou, Qing; Wu, Yi-Long","Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 510080, Guangzhou, China.; Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 510080, Guangzhou, China.; Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 510080, Guangzhou, China.; Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 510080, Guangzhou, China.; Jilin Provincial Tumor Hospital, 130012, Changchun, China.; Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 510080, Guangzhou, China.; Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 510080, Guangzhou, China.; Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 510080, Guangzhou, China.; Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 510080, Guangzhou, China.; Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 510080, Guangzhou, China.; Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 510080, Guangzhou, China. syylwu@live.cn.",syylwu@live.cn.
36822668,Predictive biomarkers for PD-1/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data.,2023,"Dejardin, David; Rossmann, Eva; Charo, Jehad","Department of Biostatistics, F Hoffmann-La Roche Ltd, Basel, Switzerland.; Roche Innovation Center Basel, F Hoffmann-La Roche Ltd, Basel, Switzerland.; Roche Innovation Center Zurich, F Hoffmann-La Roche Ltd, Schlieren, Switzerland jehad.charo@roche.com.",jehad.charo@roche.com.
36821595,RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape.,2023/May/08,"Tamma, Antonella; Puri, Tarun","Medical Oncology, Eli Lilly and Company, Indianapolis, IN, USA.; Medical Oncology, Eli Lilly and Company, Indianapolis, IN, USA.",None
36809334,The role of macrophages in non-small cell lung cancer and advancements in 3D co-cultures.,2023/Feb/21,"Clevers, Hans","Roche Pharma Research and early Development, Basel, Switzerland.",None
36808075,SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer.,2023,"Zhao, Jun; Zhou, Qing; Li, Hui; Zhang, Juan; Peng, Yanyan; Wu, Yi-Long","Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Oncology, Peking University Cancer Hospital and Institute, Beijing, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.; BeiGene (Shanghai) Co., Ltd, Shanghai, China.; BeiGene (Beijing) Co., Ltd, Beijing, China.; BeiGene (Shanghai) Co., Ltd, Shanghai, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China syylwu@live.cn.",syylwu@live.cn.
36806897,Systemic treatment and radiotherapy for patients with non-small cell lung cancer (NSCLC) and HIV infection - A systematic review.,2023,"Giaj-Levra, Niccolò","Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Via Don A.Sempreboni, 37124 Negrar di Valpolicella, Italy. Electronic address: niccolo.giajlevra@sacrocuore.it.",niccolo.giajlevra@sacrocuore.it.
36804711,The Association of Improved Overall Survival with NSAIDs in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.,2023,"Sukhatme, Vidula","Morningside Center for Innovative and Affordable Medicine, Emory University, Atlanta, GA; GlobalCures, Inc, Newton, MA.",Nikhil.Sebastian@emory.edu.
36804313,Neoadjuvant immune-checkpoint inhibitors in lung cancer - a primer for radiologists.,2023,"Kifjak, Daria; Hochmair, Maximilian J; Krenbek, Dagmar; Milos, Ruxandra-Iulia; Heidinger, Benedikt H; Prayer, Florian; Röhrich, Sebastian; Watzenboeck, Martin L; Klikovits, Thomas; Aigner, Clemens; Prosch, Helmut; Beer, Lucian","Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria; Christian Doppler Laboratory for Machine Learning Driven Precision Imaging, Medical University of Vienna, Vienna, Austria; Department of Radiology, UMass Memorial Medical Center and University of Massachusetts Chan Medical School, Worcester, MA, USA.; Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, Austria; Department of Respiratory and Critical Care Medicine, Klinik Floridsdorf, Vienna Healthcare Group, Vienna, Austria.; Department of Pathology, Klinik Floridsdorf, Vienna Healthcare Group, Vienna, Austria.; Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria; Christian Doppler Laboratory for Machine Learning Driven Precision Imaging, Medical University of Vienna, Vienna, Austria.; Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria; Christian Doppler Laboratory for Machine Learning Driven Precision Imaging, Medical University of Vienna, Vienna, Austria.; Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria; Christian Doppler Laboratory for Machine Learning Driven Precision Imaging, Medical University of Vienna, Vienna, Austria.; Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria; Christian Doppler Laboratory for Machine Learning Driven Precision Imaging, Medical University of Vienna, Vienna, Austria.; Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria; Christian Doppler Laboratory for Machine Learning Driven Precision Imaging, Medical University of Vienna, Vienna, Austria.; Department of Thoracic Surgery, Klinik Floridsdorf, Vienna Healthcare Group, Vienna, Austria.; Department of Thoracic Surgery, Klinik Floridsdorf, Vienna Healthcare Group, Vienna, Austria.; Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria; Christian Doppler Laboratory for Machine Learning Driven Precision Imaging, Medical University of Vienna, Vienna, Austria.; Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria; Christian Doppler Laboratory for Machine Learning Driven Precision Imaging, Medical University of Vienna, Vienna, Austria. Electronic address: lucian.beer@meduniwien.ac.at.",lucian.beer@meduniwien.ac.at.
36801605,"Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018.",2023,"Guisier, Florian; Chouaid, Christos; Subtil, Fabien; Martins-Lavinas, Pedro-Henrique","CHU Rouen, Service de Pneumologie, Oncologie Thoracique et Soins Intensifs Respiratoires, Normandie Univ, UNIROUEN, EA4108 LITIS Lab, QuantIF Team and Inserm CIC-CRB 1404, F-76000 Rouen, France.; CHU Rouen, Service de Pneumologie, Oncologie Thoracique et Soins Intensifs Respiratoires, Normandie Univ, UNIROUEN, EA4108 LITIS Lab, QuantIF Team and Inserm CIC-CRB 1404, F-76000 Rouen, France.; Service de Biostatistique, Hospices Civils de Lyon, Lyon, France; Université de Lyon, Université Lyon 1, CNRS, Laboratoire de Biométrie et Biologie Évolutive UMR 5558, Villeurbanne, France.; Service de Biostatistique, Hospices Civils de Lyon, Lyon, France; Université de Lyon, Université Lyon 1, CNRS, Laboratoire de Biométrie et Biologie Évolutive UMR 5558, Villeurbanne, France.",bylicki.olivier@yahoo.fr.
36789624,Progression patterns and site-specific responses in advanced gastric cancer patients treated with nivolumab.,2023,"Ushijima, Toshikazu","Division of Epigenomics, National Cancer Center Research Institute, Tokyo, Japan.",None
36787696,CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance.,2023/Feb/13,"Minna, John D","Hamon Center for Therapeutic Oncology Research, Simmons Comprehensive Cancer Center, Department of Pharmacology, The University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX, USA.",jheymach@mdanderson.org.
36776847,Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis.,2023,"Lopes, Sébastien; Dory, Anne; Gourieux, Bénédicte; Michel, Bruno","Pharmacy sterilization department, Nouvel Hopital Civil, Strasbourg University Hospital, Strasbourg, France.; Pharmacy sterilization department, Nouvel Hopital Civil, Strasbourg University Hospital, Strasbourg, France.; Pharmacy sterilization department, Nouvel Hopital Civil, Strasbourg University Hospital, Strasbourg, France.; Pharmacy sterilization department, Nouvel Hopital Civil, Strasbourg University Hospital, Strasbourg, France.",None
36765587,Treatment Strategies for Non-Small Cell Lung Cancer with Common ,2023/Jan/19,"Pellini, Bruna; Chiappori, Alberto","Department of Thoracic Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.; Department of Thoracic Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.",None
36751989,Real-world study of next-generation sequencing diagnostic biomarker testing for patients with lung cancer in Japan.,2023,"Emir, Birol; Iadeluca, Laura","Pfizer Inc., New York, USA.; Pfizer Inc., New York, USA.",None
36743523,Outcome following nivolumab treatment in patients with advanced non-small cell lung cancer and comorbid interstitial lung disease in a real-world setting.,2023,"Assié, Jean-Baptiste; Grumberg, Valentine","Functional Genomics of Solid Tumors Laboratory, Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Paris, France.; Bristol Myers Squibb France, 3 rue Joseph Monier, Rueil-Malmaison 92500, France. Oncostat - U1018, INSERM, Paris-Saclay University, ""Ligue Contre le Cancer"" Labeled Team, Villejuif, France.",None
36736322,Tissue-specific abundance of interferon-gamma drives regulatory T cells to restrain DC1-mediated priming of cytotoxic T cells against lung cancer.,2023/Feb/14,"Edwards, Austin","Biological Imaging Development CoLab, UCSF, San Francisco, CA 94143, USA.",spranger@mit.edu.
36725084,"First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817.",2023,"Spigel, David R; Li, Sunney; Chang, Han; Fiore, Joseph; Acevedo, Angelic","Department of Thoracic Medical Oncology, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee, USA.; Global Biometrics and Data Sciences, Bristol Myers Squibb, Princeton, New Jersey, USA.; Department of Translational Bioinformatics, Bristol Myers Squibb, Princeton, New Jersey, USA.; Oncology Clinical Development, Bristol Myers Squibb, Princeton, New Jersey, USA.; Oncology Clinical Development, Bristol Myers Squibb, Princeton, New Jersey, USA.",neal.ready@duke.edu.
36720323,Integral mediastinal staging in patients with NON-SMALL cell lung cancer and risk factors for occult N2 disease.,2023,"Reguart, Noemi","Medical Oncology Service, Thoracic Oncology Unit, Hospital Clínic, Barcelona, Spain; Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain.",cagusti@clinic.cat.
36697006,Next-generation sequencing and molecular therapy.,2023,"Sarker, Debashis","Guy's and St Thomas' NHS Foundation Trust, London, UK, reader in experimental oncology, King's College London, UK, and cancer lead, NHSE South East England Genomic Medicine Service and Laboratory Hub.",Cienne.morton@gstt.nhs.uk.
36689692,"Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study.",2023/Jun/01,"Johnson, Melissa L; Zhang, Yiran; Pati, Amrita; Minocha, Mukul; Mukherjee, Sujoy; Goldrick, Amanda; Nagorsen, Dirk; Hashemi Sadraei, Nooshin","Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN.; Amgen, Inc, Thousand Oaks, CA.; Amgen, Inc, Thousand Oaks, CA.; Amgen, Inc, Thousand Oaks, CA.; Amgen, Inc, Thousand Oaks, CA.; Amgen, Inc, Thousand Oaks, CA.; Amgen, Inc, Thousand Oaks, CA.; Amgen, Inc, Thousand Oaks, CA.",None
36688998,Low on-treatment levels of serum soluble CD8 (sCD8) predict better outcomes in advanced non-small cell lung cancer patients treated with atezolizumab.,2023,"Siemiątkowska, Anna; Kosicka-Noworzyń, Katarzyna; Tvrdoň, Jakub; Główka, Franciszek K","Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, 3 Rokietnicka Street, 60-806, Poznań, Poland. asiemiatkowska@ump.edu.pl.; Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, 3 Rokietnicka Street, 60-806, Poznań, Poland.; Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, 3 Rokietnicka Street, 60-806, Poznań, Poland.; Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, 3 Rokietnicka Street, 60-806, Poznań, Poland.",asiemiatkowska@ump.edu.pl.
36669791,"Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors.",2023,"Rudin, Charles M; Hill, Andrew G; Wright, Gavin M; Jennens, Ross R; Curti, Brendan D; Ren, Yixin; Schmidt, Emmett V","Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA rudinc@mskcc.org.; Tasman Oncology Research Ltd, Southport, Queensland, Australia.; Department of Surgery, St Vincent's Hospital Melbourne, The University of Melbourne, Fitzroy, Australia; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia.; Epworth Healthcare, Richmond, Victoria, Australia.; Earle A. Chiles Research Institute at Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, Oregon, USA.; Merck & Co., Inc, Rahway, New Jersey, USA.; Merck & Co., Inc, Rahway, New Jersey, USA.",rudinc@mskcc.org.
36669645,"Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.",2023,"Mok, T S","Department of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China.",None
36657815,Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer.,2023,"Palaia, Jennell; Rosenblatt, Lisa; Pisupati, Radhika; Huang, Ning; Nguyen, Chi; Barron, John; Gallagher, Kerrin; Bond, T Christopher","Worldwide Health Economics and Outcomes Research, Bristol Myers Squibb, Princeton, New Jersey, USA.; Worldwide Health Economics and Outcomes Research, Bristol Myers Squibb, Princeton, New Jersey, USA.; US Medical Oncology, Bristol Myers Squibb, Princeton, New Jersey, USA.; Worldwide Patient Safety: Medical Safety Assessment, Bristol Myers Squibb, Princeton, New Jersey, USA.; Health Economics and Outcomes Research, HealthCore Inc, Wilmington, Delaware, USA.; Health Economics and Outcomes Research, HealthCore Inc, Wilmington, Delaware, USA.; Health Economics and Outcomes Research, HealthCore Inc, Wilmington, Delaware, USA.; Worldwide Patient Safety: Epidemiology, Bristol Myers Squibb, Princeton, New Jersey, USA.",khorana@ccf.org.
36657661,Central Nervous System Disease in Patients With RET Fusion-Positive NSCLC Treated With Selpercatinib.,2023,"Liu, Dazhi","Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, New York.",drilona@mskcc.org.
36651607,Bayesian hierarchical model-based network meta-analysis to overcome survival extrapolation challenges caused by data immaturity.,2023,"Chu, Haitao; Roychoudhury, Satrajit; Cappelleri, Joseph C","Pfizer Inc, 445 Eastern Point Road, MS 8260-2502, Groton, CT 06340, USA.; Pfizer Inc, 445 Eastern Point Road, MS 8260-2502, Groton, CT 06340, USA.; Pfizer Inc, 445 Eastern Point Road, MS 8260-2502, Groton, CT 06340, USA.",None
36650021,Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis.,2023,"Huang, Richard S P; Li, Gerald; Schrock, Alexa; Graf, Ryon P; Zhang, Liangliang; Murugesan, Karthikeyan; Ross, Jeffrey S; Tolba, Khaled; Oxnard, Geoffrey R; Spigel, David","Foundation Medicine Inc, Cambridge, Massachusetts, USA rhuang@foundationmedicine.com.; Foundation Medicine Inc, Cambridge, Massachusetts, USA.; Foundation Medicine Inc, Cambridge, Massachusetts, USA.; Foundation Medicine Inc, Cambridge, Massachusetts, USA.; Foundation Medicine Inc, Cambridge, Massachusetts, USA.; Foundation Medicine Inc, Cambridge, Massachusetts, USA.; Foundation Medicine Inc, Cambridge, Massachusetts, USA.; Foundation Medicine Inc, Cambridge, Massachusetts, USA.; Foundation Medicine Inc, Cambridge, Massachusetts, USA.; Sarah Cannon Research Institute and Tennessee Oncology, Nashville, Tennessee, USA.",rhuang@foundationmedicine.com.
36639770,Evolution of treatment patterns and survival outcomes in patients with advanced non-small cell lung cancer treated at Frankfurt University Hospital in 2012-2018.,2023/Jan/13,"Penrod, John R","Worldwide Health Economics and Outcomes Research, Bristol Myers Squibb, Princeton, NJ, USA.",andreayvonne.wolf@kgu.de.
36634300,Modeling Costs and Life-Years Gained by Population-Wide Next-Generation Sequencing or Single-Gene Testing in Nonsquamous Non-Small-Cell Lung Cancer in the United States.,2023,"Zhou, Jie; Hobbs, Brian","Cleveland Clinic Lerner Research Institute, Department of Quantitative Health Sciences, Cleveland, OH.; Cleveland Clinic Lerner Research Institute, Department of Quantitative Health Sciences, Cleveland, OH.",None
36632846,RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives.,2023,"den Hollander, Petra; Mani, Sendurai A; Subbiah, Vivek","Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Pathology and Laboratory Medicine, Warren Alpert Medical School, Brown University, Providence, RI 02903, USA; Legorreta Cancer Center, Warren Alpert Medical School, Brown University, Providence, RI 02903, USA.; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Pathology and Laboratory Medicine, Warren Alpert Medical School, Brown University, Providence, RI 02903, USA; Legorreta Cancer Center, Warren Alpert Medical School, Brown University, Providence, RI 02903, USA.; Department of Investigational Cancer Therapeutics(,) Division of Cancer Medicine, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA; Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; MD Anderson Cancer Network, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: vsubbiah@mdanderson.org.",vsubbiah@mdanderson.org.
36625510,Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I.,2023/Apr/11,"Summers, Thomas J; Chao, Herta; Gray, Jhanelle E","Cookeville Regional Medical Center, Southeast NCORP, Cookeville, TN, USA.; Veterans Affairs Connecticut Healthcare System, Yale University School of Medicine, Massachusetts Veterans Epidemiology Research and Information Center, New Haven, CT, USA.; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.",None
36624315,Autologous T cell therapy for MAGE-A4,2023,"Hong, David S; Butler, Marcus O","Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. dshong@mdanderson.org.; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.",dshong@mdanderson.org.
36606486,Multistate Pharmacometric Model to Define the Impact of Second-Line Immunotherapies on the Survival Outcome of the IMpower131 Study.,2023,"Krishnan, Sreenath M; Friberg, Lena E; Mercier, François; Zhang, Rong; Wu, Ben; Jin, Jin Y; Bruno, René; Karlsson, Mats O","Department of Pharmacy, Uppsala University, Uppsala, Sweden.; Department of Pharmacy, Uppsala University, Uppsala, Sweden.; Biostatistics, F. Hoffmann-La Roche Ltd., Basel, Switzerland.; Clinical Pharmacology, Genentech, South San Francisco, California, USA.; Clinical Pharmacology, Genentech, South San Francisco, California, USA.; Clinical Pharmacology, Genentech, South San Francisco, California, USA.; Clinical Pharmacology, Roche/Genentech, Marseille, France.; Department of Pharmacy, Uppsala University, Uppsala, Sweden.",None
36599918,The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer care.,2023,"Rehal, Pauline; Rettino, Alessandro","West Midlands Regional Genetics Laboratory, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK.; West Midlands Regional Genetics Laboratory, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK.",Charles.Swanton@crick.ac.uk.
36595566,Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150.,2023/Mar/14,"Bruno, René; Yoshida, Kenta; Chan, Phyllis; Chanu, Pascal; Wu, Benjamin; Li, Chunze; Jin, Jin Y","Clinical Pharmacology, Genentech-Roche, Marseille, France.; Clinical Pharmacology, Genentech, South San Francisco, California.; Clinical Pharmacology, Genentech, South San Francisco, California.; Clinical Pharmacology, Genentech-Roche, Lyon, France.; Clinical Pharmacology, Genentech, South San Francisco, California.; Clinical Pharmacology, Genentech, South San Francisco, California.; Clinical Pharmacology, Genentech, South San Francisco, California.",None
38405208,High-dose alectinib for ,2023,"Mok, Tony; Alatorre-Alexander, Jorge; Bhagawati-Prasad, Vijay; Shagan, Sarah M; Schleifman, Erica; Ruf, Thorsten; Mathisen, Michael S","State Key Laboratory of Translational Oncology, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong.; Health Pharma Professional Research, Mexico City, Mexico.; F. Hoffmann-La Roche, Ltd., Welwyn Garden City, UK.; Genentech, Inc., South San Francisco, CA, USA.; Genentech, Inc., South San Francisco, CA, USA.; F. Hoffmann-La Roche, Ltd., Basel, Switzerland.; Genentech, Inc., South San Francisco, CA, USA.",None
36574773,The ectonucleotidase CD39 identifies tumor-reactive CD8,2023/Jan/10,"Chow, Andrew; Mangarin, Levi; Holland, Aliya; Hirschhorn, Daniel; Wolchok, Jedd D; Merghoub, Taha; Rudin, Charles M","Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA. Electronic address: chowa1@mskcc.org.; Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: tmerghoub@med.cornell.edu.; Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA; Druckenmiler Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: rudinc@mskcc.org.",rudinc@mskcc.org.
36572732,Predicting response to immune checkpoint blockade in NSCLC with tumour-only RNA-seq.,2023,"Cullerne, Darren","Murdoch Children's Research Institute, Flemington Road, Parkville, VIC, 3052, Australia.",andrew.fellowes@petermac.org.
36571770,"Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients With Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors.",2023/Mar/17,"Helwig, Christoph; Locke, George; Ojalvo, Laureen S","Merck Healthcare KGaA, Darmstadt, Germany.; EMD Serono Research & Development Institute, Inc, Billerica, MA, USA (an affiliate of Merck KGaA).; EMD Serono Research & Development Institute, Inc, Billerica, MA, USA (an affiliate of Merck KGaA).",None
36535300,"Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study.",2023,"Bauer, Todd M; Mok, Tony S K; Wu, Yi-Long","Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA.; State Key Laboratory of South China, Chinese University of Hong Kong, Hong Kong Special Administrative Region of China, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangdong, China.",ben.solomon@petermac.org.
36484171,Baseline extracellular vesicle TGF-β is a predictive biomarker for response to immune checkpoint inhibitors and survival in non-small cell lung cancer.,2023/Feb/15,"Arroyo-Hernández, Marisol; Naing, Aung; Arrieta, Oscar","Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.; Departments of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.",None
36481319,"Amivantamab, an Epidermal Growth Factor Receptor (EGFR) and Mesenchymal-epithelial Transition Factor (MET) Bispecific Antibody, Designed to Enable Multiple Mechanisms of Action and Broad Clinical Applications.",2023,"Cho, Byoung Chul","Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, 50-1 Yonsei-ro Sinchon-dong, Seodaemun-gu, Seoul, South Korea. Electronic address: CBC1971@yuhs.ac.",CBC1971@yuhs.ac.
36479637,Biomarkers predictive of response to pembrolizumab in head and neck cancer.,2023,"Ayers, Mark; Albright, Andrew; Webber, Andrea L; Mogg, Robin; Lunceford, Jared; Huang, Lingkang; Cristescu, Razvan; Cheng, Jonathan","Department of Medical Oncology, Merck & Co., Inc., Rahway, New Jersey, USA.; Department of Medical Oncology, Merck & Co., Inc., Rahway, New Jersey, USA.; Department of Medical Oncology, Merck & Co., Inc., Rahway, New Jersey, USA.; Department of Medical Oncology, Merck & Co., Inc., Rahway, New Jersey, USA.; Department of Medical Oncology, Merck & Co., Inc., Rahway, New Jersey, USA.; Department of Medical Oncology, Merck & Co., Inc., Rahway, New Jersey, USA.; Department of Medical Oncology, Merck & Co., Inc., Rahway, New Jersey, USA.; Department of Medical Oncology, Merck & Co., Inc., Rahway, New Jersey, USA.",None
36460584,Budget impact analysis of next-generation sequencing versus sequential single-gene testing in Japanese patients with advanced non-small-cell lung cancer.,2023,"Ogawa, Toru; Sadatsuki, Yasunari; Tsujino, Toshiaki","Market Access Oncology, Bayer Yakuhin, Ltd, Osaka, Japan. Electronic address: toru.ogawa@bayer.com.; Medical Affairs & Pharmacovigilance, Bayer Yakuhin, Ltd, Osaka, Japan.; Medical Affairs & Pharmacovigilance, Bayer Yakuhin, Ltd, Osaka, Japan.",toru.ogawa@bayer.com.
36453453,Transcriptional upregulation of CXCL13 is correlated with a favorable response to immune checkpoint inhibitors in lung adenocarcinoma.,2023,"Kim, Soyeon; Kim, Tae Min","Seoul National University Cancer Research Institute, Seoul, Republic of Korea.; Seoul National University Cancer Research Institute, Seoul, Republic of Korea.",None
36414192,Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis.,2023,"Ciuleanu, T-E; Pluzanski, A; Spigel, D R; O'Byrne, K J; Memaj, A; Nathan, F; Tran, P","Department of Medical Oncology, Institutul Oncologic Prof Dr Ion Chiricuta, Cluj-Napoca; Department of Medical Oncology, University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania.; Department of Lung Cancer and Chest Tumours, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.; Thoracic Medical Oncology, Sarah Cannon Research Institute/Tennessee Oncology PLCC, Nashville.; Princess Alexandra Hospital, Translational Research Institute and Queensland University of Technology, Brisbane, Australia.; Global Biometrics and Data Sciences, Bristol Myers Squibb, Princeton.; OneClinical, Bristol Myers Squibb, Princeton.; WW Medical Oncology Department, Bristol Myers Squibb, Princeton.",hossein.borghaei@fccc.edu.
36413252,Renal function-based versus standard dosing of pemetrexed: a randomized controlled trial.,2023,"de Rouw, Nikki; Boosman, René J; Huitema, Alwin D R; Derijks, Hieronymus J; Burger, David M; Croes, Sander; Ter Heine, Rob","Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center Nijmegen, Nijmegen, The Netherlands.; Department of Pharmacy & Pharmacology, Antoni Van Leeuwenhoek-The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. r.boosman@nki.nl.; Department of Pharmacy & Pharmacology, Antoni Van Leeuwenhoek-The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.; Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center Nijmegen, Nijmegen, The Netherlands.; Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center Nijmegen, Nijmegen, The Netherlands.; Department of Clinical Pharmacy & Toxicology, CARIM-School for Cardiovascular Disease, Maastricht University Medical Centre, Maastricht, The Netherlands.; Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center Nijmegen, Nijmegen, The Netherlands.",r.boosman@nki.nl.
36404632,"Five-year survival and clinical correlates among patients with advanced non-small cell lung cancer, melanoma and renal cell carcinoma treated with immune check-point inhibitors in Australian tertiary oncology centres.",2023,"Brown, Lauren J; Moujaber, Tania; Gao, Bo; Hui, Rina; Gurney, Howard; Carlino, Matteo; Nagrial, Adnan","Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, New South Wales, Australia.; Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, New South Wales, Australia.; Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, New South Wales, Australia.; Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, New South Wales, Australia.; Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, New South Wales, Australia.; Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, New South Wales, Australia.; Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, New South Wales, Australia.",None
36403367,"Protective effect of obesity on survival in cancers treated with immunotherapy vanishes when controlling for type of cancer, weight loss and reduced skeletal muscle.",2023,"Voisin, Anne Laure; Messayke, Sabine; Laghouati, Salim","Unité de Pharmacovigilance, Gustave Roussy, Université Paris-Saclay, F-94800, Villejuif, France.; Unité de Pharmacovigilance, Gustave Roussy, Université Paris-Saclay, F-94800, Villejuif, France.; Unité de Pharmacovigilance, Gustave Roussy, Université Paris-Saclay, F-94800, Villejuif, France.",sami.antoun@gustaveroussy.fr.
36394849,Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial.,2023/Jan/01,"Dvorkin, Michael","Clinical Oncology Dispensary, Budget Healthcare Institution of Omsk Region, Omsk, Russian Federation.",None
36369159,Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lung cancer.,2023,"Nicholas, Alan; Schulze, Katja; Johnson, Ann","Genentech, Inc, South San Francisco, Calif.; Genentech, Inc, South San Francisco, Calif.; Genentech, Inc, South San Francisco, Calif.",ruschv@mskcc.org.
36240971,Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228.,2023,"Fan, Pang-Dian","Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Current Affiliation, Daiichi Sankyo, Inc., Basking Ridge, New Jersey.",paikp@mskcc.org.
36058839,Change in four measures of physical function among older adults during lung cancer treatment: A mixed methods cohort study.,2023,"Williams, Grant R","Divisions of Hematology/Oncology and Gerontology, Geriatrics, and Palliative Care, The University of Alabama at Birmingham, Birmingham, AL, USA.",melisa.wong@ucsf.edu.
36054490,Phase 1 trial of CV301 in combination with anti-PD-1 therapy in nonsquamous non-small cell lung cancer.,2023/Feb/01,"Donahue, Renee N; Schlom, Jeffrey; Gulley, James L","Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.; Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.; Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.",None
35881197,Comparison of the tumor immune microenvironment and checkpoint blockade biomarkers between stage III and IV non-small cell lung cancer.,2023,"Gao, Yinjie; Stein, Michelle M; Kase, Matthew; Bharanikumar, Ramit; Lau, Denise","Tempus Labs, Chicago, IL, 60654, USA.; Tempus Labs, Chicago, IL, 60654, USA.; Tempus Labs, Chicago, IL, 60654, USA.; Tempus Labs, Chicago, IL, 60654, USA.; Tempus Labs, Chicago, IL, 60654, USA.",SPatel@Health.UCSD.edu.
35838839,Selective RET inhibitors shift the treatment pattern of RET fusion-positive NSCLC and improve survival outcomes.,2023,"Wei, Xue-Wu; Zhang, Yi-Chen; Chen, Zhi-Hong; Xu, Chong-Rui; Zheng, Ming-Ying; Yang, Jin-Ji; Zhang, Xu-Chao","Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, China.",gzzhouqing@126.com.
35532791,Clinical benefit and cost-effectiveness analysis of liquid biopsy application in patients with advanced non-small cell lung cancer (NSCLC): a modelling approach.,2023,"Englmeier, Fabienne; Nagels, Klaus","Chair of Healthcare Management and Health Services Research, University of Bayreuth, Parsifalstraße 25, 95445, Bayreuth, Germany.; Chair of Healthcare Management and Health Services Research, University of Bayreuth, Parsifalstraße 25, 95445, Bayreuth, Germany. klaus.nagels@uni-bayreuth.de.",klaus.nagels@uni-bayreuth.de.
38116246,APOBEC3 as a driver of genetic intratumor heterogeneity.,2023,"Venkatesan, Subramanian; Angelova, Mihaela; Swanton, Charles","Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.",None
